NO20040453L - Antistoff glykosyleringsvarianter med okt antistoff-avhengig cellulaer cytotoksisitet - Google Patents

Antistoff glykosyleringsvarianter med okt antistoff-avhengig cellulaer cytotoksisitet

Info

Publication number: NO20040453L
Authority: NO; Norway
Prior art keywords: antibody; oct; dependent cellular; cellular cytotoxicity; glycosylation variants
Prior art date: 2001-08-03

Application number

NO20040453A

Other languages

English (en)

Other versions

NO332457B1 (no

Inventor

James E Bailey

Joel Jean-Mairet

Pablo Umana

Original Assignee

Glycart Biotechnology Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-08-03

Filing date

2004-02-02

Publication date

2004-03-30

2004-02-02 Application filed by Glycart Biotechnology Ag filed Critical Glycart Biotechnology Ag

2004-03-30 Publication of NO20040453L publication Critical patent/NO20040453L/no

2012-09-24 Publication of NO332457B1 publication Critical patent/NO332457B1/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3038—Kidney, bladder
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1051—Hexosyltransferases (2.4.1)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/52—Improvements relating to the production of bulk chemicals using catalysts, e.g. selective catalysts

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Genetics & Genomics (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
General Engineering & Computer Science (AREA)
Microbiology (AREA)
Biomedical Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Urology & Nephrology (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Radiology & Medical Imaging (AREA)
Epidemiology (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO20040453A 2001-08-03 2004-02-02 Glykomodifisert antistoff for anvendelse i behandling NO332457B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US30951601P	2001-08-03	2001-08-03
PCT/US2002/024739 WO2003011878A2 (en)	2001-08-03	2002-08-05	Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity

Publications (2)

Publication Number	Publication Date
NO20040453L true NO20040453L (no)	2004-03-30
NO332457B1 NO332457B1 (no)	2012-09-24

Family

ID=23198536

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20040453A NO332457B1 (no)	2001-08-03	2004-02-02	Glykomodifisert antistoff for anvendelse i behandling

Country Status (15)

Country	Link
US (5)	US20030175884A1 (no)
EP (2)	EP2180044A1 (no)
JP (2)	JP2005524379A (no)
KR (2)	KR20040054669A (no)
CN (1)	CN1555411A (no)
AU (1)	AU2002339845B2 (no)
CA (2)	CA2838062C (no)
HU (1)	HUP0700103A3 (no)
IL (2)	IL160170A0 (no)
MX (1)	MXPA04001072A (no)
NO (1)	NO332457B1 (no)
NZ (5)	NZ531219A (no)
PL (1)	PL217751B1 (no)
RU (1)	RU2321630C2 (no)
WO (1)	WO2003011878A2 (no)

Families Citing this family (959)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6136311A (en)	1996-05-06	2000-10-24	Cornell Research Foundation, Inc.	Treatment and diagnosis of cancer
ES2340112T3 (es)	1998-04-20	2010-05-28	Glycart Biotechnology Ag	Ingenieria de glicosilacion de anticuerpos para la mejora de la citotoxicidad celular dependiente de anticuerpos.
IL143641A0 (en)	1998-12-09	2002-04-21		A method for manufacturing glycoproteins having human-type glycosylation
ATE464907T1 (de)	1999-02-17	2010-05-15	Csl Ltd	Immunogene komplexe und methoden in bezug auf diese
ATE478150T1 (de)	1999-10-26	2010-09-15	Stichting Dienst Landbouwkundi	Säugetierartige glykosylierung in pflanzen
IL151348A0 (en) *	2000-04-13	2003-04-10	Univ Rockefeller	Enhancement of antibody-mediated immune responses
EP1297172B1 (en) *	2000-06-28	2005-11-09	Glycofi, Inc.	Methods for producing modified glycoproteins
US7598055B2 (en)	2000-06-28	2009-10-06	Glycofi, Inc.	N-acetylglucosaminyltransferase III expression in lower eukaryotes
US8697394B2 (en) *	2000-06-28	2014-04-15	Glycofi, Inc.	Production of modified glycoproteins having multiple antennary structures
US7449308B2 (en)	2000-06-28	2008-11-11	Glycofi, Inc.	Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
CN100385006C (zh)	2001-01-19	2008-04-30	陶氏化学公司	利用植物细胞分泌性生产具有人型糖链的糖蛋白的方法
CA2442801A1 (en) *	2001-04-02	2002-10-10	Idec Pharmaceutical Corporation	Recombinant antibodies coexpressed with gntiii
PL217751B1 (pl)	2001-08-03	2014-08-29	Glycart Biotechnology Ag	Zastosowanie glikomodyfikowanego przeciwciała do wytwarzania kompozycji farmaceutycznej do leczenia choroby wybranej z grupy składającej się z nowotworu, małopłytkowości autoimmunologicznej w przewlekłej chorobie przeszczep przeciwko gospodarzowi i immunozależnej nabytej aplazji czysto czerwonokrwinkowej
AU2002357359B2 (en) *	2001-12-21	2009-01-08	Csl Limited	Compositions comprising immunoreactive reagents and saponins, and methods of use thereof
US20040132101A1 (en)	2002-09-27	2004-07-08	Xencor	Optimized Fc variants and methods for their generation
US20080260731A1 (en) *	2002-03-01	2008-10-23	Bernett Matthew J	Optimized antibodies that target cd19
US20070148171A1 (en) *	2002-09-27	2007-06-28	Xencor, Inc.	Optimized anti-CD30 antibodies
US8188231B2 (en)	2002-09-27	2012-05-29	Xencor, Inc.	Optimized FC variants
US7662925B2 (en) *	2002-03-01	2010-02-16	Xencor, Inc.	Optimized Fc variants and methods for their generation
US20080254027A1 (en) *	2002-03-01	2008-10-16	Bernett Matthew J	Optimized CD5 antibodies and methods of using the same
US7317091B2 (en)	2002-03-01	2008-01-08	Xencor, Inc.	Optimized Fc variants
EP1485492B1 (en) *	2002-03-19	2011-12-21	Stichting Dienst Landbouwkundig Onderzoek	Gntiii (udp-n-acetylglucosamine:beta-d mannoside beta(1,4)-n-acetylglucosaminyltransferase iii) expression in plants
CA2478297C (en)	2002-03-19	2013-05-14	Plant Research International B.V.	Optimizing glycan processing in plants
US20060235208A1 (en) *	2002-09-27	2006-10-19	Xencor, Inc.	Fc variants with optimized properties
AR042145A1 (es)	2002-11-27	2005-06-08	Dow Agrociences Llc	Produccion de inmunoglobulinas en plantas con una fucocilacion reducida
EP1590437A4 (en) *	2003-01-24	2008-06-18	Agensys Inc	NUCLEIC ACIDS SUITABLE FOR THE TREATMENT AND DETECTION OF CANCER AND CORRESPONDING PROTEINS NAMED 254P1D6B
US7332299B2 (en)	2003-02-20	2008-02-19	Glycofi, Inc.	Endomannosidases in the modification of glycoproteins in eukaryotes
US20090010920A1 (en)	2003-03-03	2009-01-08	Xencor, Inc.	Fc Variants Having Decreased Affinity for FcyRIIb
US20070275460A1 (en) *	2003-03-03	2007-11-29	Xencor.Inc.	Fc Variants With Optimized Fc Receptor Binding Properties
US8084582B2 (en)	2003-03-03	2011-12-27	Xencor, Inc.	Optimized anti-CD20 monoclonal antibodies having Fc variants
US8388955B2 (en)	2003-03-03	2013-03-05	Xencor, Inc.	Fc variants
US9051373B2 (en)	2003-05-02	2015-06-09	Xencor, Inc.	Optimized Fc variants
AR044388A1 (es)	2003-05-20	2005-09-07	Applied Molecular Evolution	Moleculas de union a cd20
US8101720B2 (en)	2004-10-21	2012-01-24	Xencor, Inc.	Immunoglobulin insertions, deletions and substitutions
US9714282B2 (en)	2003-09-26	2017-07-25	Xencor, Inc.	Optimized Fc variants and methods for their generation
US20070148170A1 (en) *	2005-10-03	2007-06-28	Desjarlais John R	Fc Variants With Optimized Fc Receptor Binding Properties
NZ588860A (en) *	2003-11-05	2012-03-30	Roche Glycart Ag	CD20 antibodies with increased Fc receptor binding affinity and effector function
EP1697520A2 (en) *	2003-12-22	2006-09-06	Xencor, Inc.	Fc polypeptides with novel fc ligand binding sites
EP3653641A1 (en)	2004-02-19	2020-05-20	Genentech, Inc.	Cdr-repaired antibodies
TW200539855A (en) *	2004-03-15	2005-12-16	Wyeth Corp	Calicheamicin conjugates
CA2561264A1 (en) *	2004-03-24	2005-10-06	Xencor, Inc.	Immunoglobulin variants outside the fc region
BRPI0509412A (pt) *	2004-04-16	2007-09-04	Genentech Inc	método de tratamento de policondrite ou mononeurite multiplex em mamìferos e artigo industrializado
EP3130349A1 (en)	2004-06-04	2017-02-15	Genentech, Inc.	Method for treating multiple sclerosis
EP2314317A3 (en) *	2004-07-09	2011-06-29	Chugai Seiyaku Kabushiki Kaisha	Anti-glypican 3 antibody
WO2006005367A1 (en) *	2004-07-14	2006-01-19	Igeneon Krebs-Immuntherapie Forschungs-Und Entwicklungs-Ag	N-glycosylated antibody
US20150010550A1 (en)	2004-07-15	2015-01-08	Xencor, Inc.	OPTIMIZED Fc VARIANTS
US20060074225A1 (en) *	2004-09-14	2006-04-06	Xencor, Inc.	Monomeric immunoglobulin Fc domains
EP1812060A2 (en)	2004-10-05	2007-08-01	Genentech, Inc.	Method for treating vasculitis
JO3000B1 (ar)	2004-10-20	2016-09-05	Genentech Inc	مركبات أجسام مضادة .
CA2585196C (en) *	2004-10-26	2015-01-06	Chugai Seiyaku Kabushiki Kaisha	Anti-glypican 3 antibody having modified sugar chain
US8367805B2 (en)	2004-11-12	2013-02-05	Xencor, Inc.	Fc variants with altered binding to FcRn
CA2587617C (en)	2004-11-12	2011-02-01	Xencor, Inc.	Fc variants with altered binding to fcrn
US8546543B2 (en)	2004-11-12	2013-10-01	Xencor, Inc.	Fc variants that extend antibody half-life
US8802820B2 (en)	2004-11-12	2014-08-12	Xencor, Inc.	Fc variants with altered binding to FcRn
CA2595169A1 (en) *	2005-01-12	2006-07-20	Xencor, Inc.	Antibodies and fc fusion proteins with altered immunogenicity
MX2007008768A (es)	2005-01-21	2007-10-19	Genentech Inc	Dosificacion fija de anticuerpos her.
TWI387602B (zh)	2005-02-07	2013-03-01	Roche Glycart Ag	與上皮生長因子受體（ｅｇｆｒ）結合之抗原結合分子，編碼該抗原結合分子之載體及其用途
BRPI0607203A2 (pt) *	2005-02-18	2009-08-25	Medarex Inc	anticorpo anti-cd30 isolado, célula hospedeira, métodos para inibir o crescimento de células cd30+, e, uso de um anticorpo anti-cd30 desfucosilado
RU2404806C2 (ru)	2005-02-23	2010-11-27	Дженентек, Инк.	Продление времени до прогрессирования заболевания или продолжительности жизни у онкологических больных с применением ингибиторов димеризации her
TW200720439A (en) *	2005-03-25	2007-06-01	Glycart Biotechnology Ag	Antigen binding molecules directed to mcsp and having increased fc receptor binding affinity and effector function
JO3058B1 (ar)	2005-04-29	2017-03-15	Applied Molecular Evolution Inc	الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها
EP1888649A2 (en) *	2005-05-09	2008-02-20	GlycArt Biotechnology AG	Antigen binding molecules having modified fc regions and altered binding to fc receptors
ZA200710496B (en) *	2005-06-02	2009-04-29	Astrazeneca Ab	Antibodies directed to CD20 and used thereof
JP2008541770A (ja) *	2005-06-03	2008-11-27	ジェネンテック・インコーポレーテッド	改変したフコシル化レベルを有する抗体の産生方法
SI1896073T1 (sl)	2005-06-30	2013-06-28	Janssen Biotech, Inc.	Protitelesa proti il-23, sestavki, prostopki in uporabe
ES2530265T3 (es)	2005-07-21	2015-02-27	Genmab A/S	Ensayos de potencia de unión de una sustancia medicamentosa de anticuerpo a un receptor FC
CA2619825A1 (en) *	2005-08-19	2007-03-01	Centocor, Inc.	Proteolysis resistant antibody preparations
RU2482132C2 (ru) *	2005-08-26	2013-05-20	Роше Гликарт Аг	Модифицированные антигенсвязывающие молекулы с измененной клеточной сигнальной активностью
US7973136B2 (en) *	2005-10-06	2011-07-05	Xencor, Inc.	Optimized anti-CD30 antibodies
US20070087005A1 (en) *	2005-10-14	2007-04-19	Lazar Gregory A	Anti-glypican-3 antibody
MY149159A (en)	2005-11-15	2013-07-31	Hoffmann La Roche	Method for treating joint damage
RU2426742C2 (ru)	2005-12-02	2011-08-20	Дженентек, Инк.	Составы и способы лечения заболеваний и нарушений, связанных с передачей сигналов цитокинами
MY162559A (en)	2005-12-29	2017-06-15	Centocor Inc	Human anti-il-23 antibodies, compositions, methods and uses
CA2638785C (en)	2006-01-05	2017-02-21	Genentech, Inc.	Anti-ephb4 antibodies and methods using same
US20070166306A1 (en) *	2006-01-17	2007-07-19	Fey Georg H M	Anti-CD19 antibody composition and method
JP2009523432A (ja)	2006-01-17	2009-06-25	バイオレックスセラピュティックスインク	植物中でのｎ−グリカンのヒト化及び最適化のための組成物及び方法
EP2623986B1 (en) *	2006-02-10	2017-06-14	Life Technologies Corporation	Labeling and detection of post translationally modified proteins
AR059851A1 (es)	2006-03-16	2008-04-30	Genentech Inc	Anticuerpos de la egfl7 y metodos de uso
ATE509033T1 (de)	2006-03-20	2011-05-15	Univ California	Manipulierte anti-prostatastammzellenantigen (psca)-antikörper für krebs-targeting
RS54163B1 (en)	2006-05-30	2015-12-31	Genentech Inc.	ANTI-CD22 ANTIBODIES, THEIR IMMUNCONJUGATES AND THEIR USE
SG175615A1 (en)	2006-06-06	2011-11-28	Genentech Inc	Anti-dll4 antibodies and methods using same
ME01758B (me)	2006-07-14	2014-09-20	Genentech Inc	Humanizirano protutijelo protiv amiloida beta
EP2468770B1 (en)	2006-07-14	2017-12-20	AC Immune S.A.	Humanized antibody against amyloid beta.
JP2009543579A (ja)	2006-07-19	2009-12-10	ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア	抗炎症反応のための標的としてのＷＳＸ−１／ｐ２８
AR062223A1 (es) *	2006-08-09	2008-10-22	Glycart Biotechnology Ag	Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
RS53263B (en)	2006-08-14	2014-08-29	Xencor Inc.	CD19 OPTIMIZED ANTIBODY
US8911964B2 (en)	2006-09-13	2014-12-16	Abbvie Inc.	Fed-batch method of making human anti-TNF-alpha antibody
CA2663442A1 (en)	2006-09-13	2008-03-20	Abbott Laboratories	Cell culture improvements
US8394374B2 (en) *	2006-09-18	2013-03-12	Xencor, Inc.	Optimized antibodies that target HM1.24
AR063257A1 (es) *	2006-10-12	2009-01-14	Genentech Inc	Anticuerpos anti-linfotoxina alfa
DK2845866T3 (en)	2006-10-27	2017-07-10	Genentech Inc	Antibodies and immunoconjugates and their applications
CN101626782B (zh) *	2006-12-01	2013-03-27	梅达雷克斯公司	结合cd22的人抗体及其用途
EP2468776A3 (en)	2007-02-09	2012-11-14	Genentech, Inc.	Anti-Robo4 antibodies and uses therefor
CN101680897B (zh)	2007-03-02	2013-11-13	健泰科生物技术公司	基于低her3表达预测对her二聚化抑制剂的响应
SG187521A1 (en) *	2007-03-07	2013-02-28	Glycofi Inc	Production of glycoproteins with modified fucosylation
US7960139B2 (en)	2007-03-23	2011-06-14	Academia Sinica	Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
BRPI0810443A2 (pt)	2007-04-17	2016-09-27	Plant Res Int Bv	glicosilação do tipo em mamífero em plantas através da expressão de glicosiltransferases de não mamíferos
WO2008143878A1 (en)	2007-05-14	2008-11-27	Medimmune, Llc	Methods of reducing eosinophil levels
EP2592156B1 (en)	2007-06-08	2016-04-20	Genentech, Inc.	Gene expression markers of tumor resistance to HER2 inhibitor treatment
WO2008156622A1 (en)	2007-06-12	2008-12-24	Ac Immune S.A.	Humanized antibodies to amyloid beta
BRPI0812538B1 (pt) *	2007-06-15	2021-03-16	Medicago Inc.	processo para a síntese de uma proteína de interesse com fucosilação e xilosilação reduzidas, ácido nucleico, e proteína híbrida gnt1-galt
US7580304B2 (en) *	2007-06-15	2009-08-25	United Memories, Inc.	Multiple bus charge sharing
JP5687057B2 (ja)	2007-07-09	2015-03-18	ジェネンテック，インコーポレイテッド	ポリペプチドの組換え生産中におけるジスルフィド結合還元の防止
US8940298B2 (en)	2007-09-04	2015-01-27	The Regents Of The University Of California	High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection
ES2687808T3 (es)	2007-09-26	2018-10-29	Chugai Seiyaku Kabushiki Kaisha	Región constante de anticuerpo modificado
BRPI0818623A2 (pt)	2007-10-05	2017-05-23	Ac Immune Sa	composição farmacêutica, e, métodos para reduzir a carga da placa na camada de célula de gânglio retinal de um animal, para reduzir a quantidade de placas na camada de célula de gânglio retinal de um animal, para diminuir a quantidade total de amilóide-beta solúvel na camada de célula de gânglio retinal de um animal, para prevenir, tratar e/ou aliviar os efeitos de uma doença ocular associada com anormalidades patológicas/mudanças no tecido do sistema visual, para monitorar doença ocular residual mínima associada com anormalidades patológicas/mudanças nos tecidos do sistema visual, para predizer responsividade de um paciente, e para reter ou diminuir a pressão ocular nos olhos de um animal
US20090202475A1 (en)	2007-11-07	2009-08-13	Genentech, Inc.	Compositions and methods for treatment of microbial disorders
AR069501A1 (es)	2007-11-30	2010-01-27	Genentech Inc	Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
WO2009086072A2 (en) *	2007-12-21	2009-07-09	Genentech, Inc.	Therapy of rituximab-refractory rheumatoid arthritis patients
DK2235059T3 (en)	2007-12-26	2015-03-30	Xencor Inc	FC-VERSIONS OF MODIFIED BINDING TO FcRn
HUE024291T2 (en) *	2007-12-26	2016-01-28	Biotest Ag	Immunoconjugates and Applications for CD138
WO2009080832A1 (en) *	2007-12-26	2009-07-02	Biotest Ag	Methods and agents for improving targeting of cd138 expressing tumor cells
EP2238169A1 (en) *	2007-12-26	2010-10-13	Biotest AG	Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates
EP2238168B8 (en) *	2007-12-26	2014-07-23	Biotest AG	Agents targeting cd138 and uses thereof
TWI472339B (zh)	2008-01-30	2015-02-11	Genentech Inc	包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
WO2009134738A1 (en) *	2008-04-29	2009-11-05	Genentech, Inc.	Responses to immunizations in rheumatoid arthritis patients treated with a cd20 antibody
KR101054362B1 (ko) *	2008-07-03	2011-08-05	재단법인 목암생명공학연구소	재조합 단백질의 푸코스 함량을 감소시키는 방법
ES2442024T3 (es)	2008-07-15	2014-02-07	Academia Sinica	Matrices de glucano sobre portaobjetos de vidrio revestidos con aluminio de tipo PTFE y métodos relacionados
TW201014605A (en)	2008-09-16	2010-04-16	Genentech Inc	Methods for treating progressive multiple sclerosis
US8025879B2 (en) *	2008-09-26	2011-09-27	Eureka Therapeutics, Inc.	Modified glycoproteins and uses thereof
BRPI0914091B1 (pt)	2008-10-14	2022-05-10	Genentech Inc	Igg variante, composição farmacêutica, kit e usos de um igg variante
EP2346897A2 (en)	2008-10-20	2011-07-27	Abbott Laboratories	Viral inactivation during purification of antibodies
SG10201702922VA (en)	2008-10-20	2017-06-29	Abbvie Inc	Isolation and purification of antibodies using protein a affinity chromatography
US20100143351A1 (en)	2008-11-22	2010-06-10	Genentech, Inc.	Anti-Angiogenesis Therapy for the Treatment of Breast Cancer
AR074777A1 (es)	2008-12-19	2011-02-09	Glaxo Group Ltd	Proteinas de union a antigeno
WO2010075249A2 (en)	2008-12-22	2010-07-01	Genentech, Inc.	A method for treating rheumatoid arthritis with b-cell antagonists
KR101812811B1 (ko)	2008-12-23	2017-12-27	제넨테크, 인크.	단백질 ａ에 대해 변경된 결합을 갖는 이뮤노글로불린 변이체
EP2398504B1 (en)	2009-02-17	2018-11-28	Cornell Research Foundation, Inc.	Methods and kits for diagnosis of cancer and prediction of therapeutic value
EP2401696B1 (en) *	2009-02-26	2017-06-21	Intrexon CEU, Inc.	Mammalian cell line models and related methods
MA33198B1 (fr)	2009-03-20	2012-04-02	Genentech Inc	Anticorps anti-her di-spécifiques
CN102378767B (zh)	2009-03-25	2015-01-14	健泰科生物技术公司	抗-fgfr3抗体及其使用方法
JP6051048B2 (ja)	2009-03-25	2016-12-21	ジェネンテック，インコーポレイテッド	新規な抗α５β１抗体及びその使用
MX2011010168A (es)	2009-04-07	2011-10-11	Roche Glycart Ag	Anticuerpos biespecificos, trivalentes.
CN102573916B (zh) *	2009-05-06	2017-05-17	生物测试股份公司	靶向cd138的免疫偶联物的应用
WO2010138184A2 (en)	2009-05-27	2010-12-02	Synageva Biopharma Corp.	Avian derived antibodies
US9676845B2 (en)	2009-06-16	2017-06-13	Hoffmann-La Roche, Inc.	Bispecific antigen binding proteins
WO2010146059A2 (en)	2009-06-16	2010-12-23	F. Hoffmann-La Roche Ag	Biomarkers for igf-1r inhibitor therapy
TW201106972A (en)	2009-07-27	2011-03-01	Genentech Inc	Combination treatments
CN102498129B (zh)	2009-07-31	2016-03-02	霍夫曼-拉罗奇有限公司	使用bv8拮抗剂或g-csf拮抗剂抑制肿瘤转移
SG178358A1 (en)	2009-08-11	2012-03-29	Genentech Inc	Production of proteins in glutamine-free cell culture media
CN102573909A (zh)	2009-08-15	2012-07-11	霍夫曼-拉罗奇有限公司	抗血管发生疗法用于治疗先前治疗过的乳腺癌
TWI412375B (zh)	2009-08-28	2013-10-21	Roche Glycart Ag	人類化抗ｃｄｃｐ１抗體
AU2010288469A1 (en) *	2009-08-31	2012-03-01	Roche Glycart Ag	Affinity-matured humanized anti CEA monoclonal antibodies
WO2011028952A1 (en)	2009-09-02	2011-03-10	Xencor, Inc.	Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US9321823B2 (en)	2009-09-02	2016-04-26	Genentech, Inc.	Mutant smoothened and methods of using the same
BR112012009412A2 (pt)	2009-10-22	2016-11-29	Genentech Inc	'anticorpo anti-hepsina isolado, molécula de ácido nucleico, célula hospedeira, método para fabricar um anticorpo, imunoconjugado, formulação farmacêutica, uso do anticorpo e método para fabricar um anticorpo anti-serina protease'
WO2011056494A1 (en)	2009-10-26	2011-05-12	Genentech, Inc.	Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
WO2011056497A1 (en)	2009-10-26	2011-05-12	Genentech, Inc.	Activin receptor type iib compositions and methods of use
WO2011056502A1 (en)	2009-10-26	2011-05-12	Genentech, Inc.	Bone morphogenetic protein receptor type ii compositions and methods of use
JP6007420B2 (ja)	2009-11-04	2016-10-12	ファブラスエルエルシー	親和性成熟に基づく抗体最適化方法
EP2496601B1 (en)	2009-11-05	2017-06-07	F. Hoffmann-La Roche AG	Methods and composition for secretion of heterologous polypeptides
JP6251477B2 (ja)	2009-12-02	2017-12-20	イマジナブ・インコーポレーテッド	ヒト前立腺特異的膜抗原（ｐｓｍａ）をターゲッティングするｊ５９１ミニボディおよびｃｙｓダイアボディならびにこれらを使用するための方法
US11377485B2 (en)	2009-12-02	2022-07-05	Academia Sinica	Methods for modifying human antibodies by glycan engineering
US10087236B2 (en)	2009-12-02	2018-10-02	Academia Sinica	Methods for modifying human antibodies by glycan engineering
AR078377A1 (es)	2009-12-11	2011-11-02	Genentech Inc	Anticuerpos anti-vegf-c (factor de crecimiento endotelial anti-vascular aislado c) y sus metodos de uso
RU2559542C2 (ru)	2009-12-23	2015-08-10	Дженентек, Инк.	Антитела против bv8 и их применение
WO2011091078A2 (en)	2010-01-19	2011-07-28	Xencor, Inc.	Antibody fc variants with enhanced complement activity
MA34004B1 (fr)	2010-01-28	2013-02-01	Glaxo Group Ltd	Protéines de liaison à cd127
US20120308564A1 (en)	2010-02-09	2012-12-06	Andrew Ian Bayliffe	Treatment of a metabolic disorder
EP2533810B1 (en)	2010-02-10	2016-10-12	ImmunoGen, Inc.	Cd20 antibodies and uses thereof
ES2519348T3 (es)	2010-02-18	2014-11-06	Genentech, Inc.	Antagonistas de neurregulina y uso de los mismos en el tratamiento del cáncer
US20110200595A1 (en)	2010-02-18	2011-08-18	Roche Glycart	TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR
KR20180028561A (ko)	2010-02-23	2018-03-16	제넨테크, 인크.	난소암의 치료를 위한 항혈관신생 요법
UA108227C2 (xx)	2010-03-03	2015-04-10		Антигензв'язуючий білок
JP6093692B2 (ja)	2010-03-24	2017-03-08	ジェネンテック，インコーポレイテッド	抗ｌｒｐ６抗体
WO2011124635A1 (en)	2010-04-07	2011-10-13	Humalys	Binding molecules against chikungunya virus and uses thereof
EP2374816B1 (en)	2010-04-07	2016-09-28	Agency For Science, Technology And Research	Binding molecules against Chikungunya virus and uses thereof
WO2011130332A1 (en)	2010-04-12	2011-10-20	Academia Sinica	Glycan arrays for high throughput screening of viruses
CA2835489C (en)	2010-05-10	2018-03-06	Chi-Huey Wong	Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
WO2011146568A1 (en)	2010-05-19	2011-11-24	Genentech, Inc.	Predicting response to a her inhibitor
WO2011147834A1 (en)	2010-05-26	2011-12-01	Roche Glycart Ag	Antibodies against cd19 and uses thereof
WO2011153243A2 (en)	2010-06-02	2011-12-08	Genentech, Inc.	Anti-angiogenesis therapy for treating gastric cancer
NZ602840A (en)	2010-06-03	2014-11-28	Genentech Inc	Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
AR081556A1 (es)	2010-06-03	2012-10-03	Glaxo Group Ltd	Proteinas de union al antigeno humanizadas
BR112012027995A2 (pt)	2010-06-18	2017-01-10	Genentech Inc	anticorpo e ácido nucleíco isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, uso do anticorpo, método de tratamento de um indivíduo com câncer, de um indivíduo possuíndo um distúrbio imune, de inibição da angiogênese e para inibir a ativação constitutiva de axl
WO2011161119A1 (en)	2010-06-22	2011-12-29	F. Hoffmann-La Roche Ag	Antibodies against insulin-like growth factor i receptor and uses thereof
WO2011161189A1 (en)	2010-06-24	2011-12-29	F. Hoffmann-La Roche Ag	Anti-hepsin antibodies and methods of use
NZ605449A (en)	2010-07-09	2015-03-27	Genentech Inc	Anti-neuropilin antibodies and methods of use
EP2409993A1 (en)	2010-07-19	2012-01-25	International-Drug-Development-Biotech	Anti-CD19 antibody having ADCC function with improved glycosylation profile
EP2409712A1 (en)	2010-07-19	2012-01-25	International-Drug-Development-Biotech	Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
EP2409989A1 (en)	2010-07-19	2012-01-25	International-Drug-Development-Biotech	Method to improve glycosylation profile for antibody
WO2012010582A1 (en)	2010-07-21	2012-01-26	Roche Glycart Ag	Anti-cxcr5 antibodies and methods of use
AU2011280969A1 (en)	2010-07-23	2013-02-07	Trustees Of Boston University	Anti-Despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
BR112013002535A2 (pt)	2010-08-03	2019-09-24	Hoffmann La Roche	biomarcadores de leucemia linfocítica crônica (cll)
BR112013002532A2 (pt)	2010-08-05	2016-05-31	Hoffmann La Roche	proteína de fusão de citocina anti-viral do anticorpo anti-mhc
PT2603530T (pt)	2010-08-13	2018-01-09	Roche Glycart Ag	Anticorpos anti-fap e métodos de utilização
MX2013001336A (es)	2010-08-13	2013-03-08	Roche Glycart Ag	Anticuerpos ani-tenascina c a2 y metodos de utilizacion.
KR101603001B1 (ko)	2010-08-25	2016-03-11	에프. 호프만-라 로슈 아게	Il-18r1에 대한 항체 및 그의 용도
JP2013537966A (ja)	2010-08-31	2013-10-07	ジェネンテック，インコーポレイテッド	バイオマーカー及び治療の方法
US8481680B2 (en)	2010-10-05	2013-07-09	Genentech, Inc.	Mutant smoothened and methods of using the same
EP3351559A3 (en)	2010-11-08	2018-10-31	F. Hoffmann-La Roche AG	Subcutaneously administered anti-il-6 receptor antibody
EP3176184B1 (en)	2010-11-10	2020-02-19	F. Hoffmann-La Roche AG	Anti-bace1 antibodies for neural disease immunotherapy
BR112013012627A2 (pt)	2010-11-23	2016-10-04	Glaxo Group Ltd	proteína de ligação de antígeno, polinucleotídeo, composição farmacêutica, e uso da referida composição
MX2013005847A (es)	2010-11-24	2013-12-12	Glaxo Group Ltd	Proteinas de union a antigeno multiespecificas que eligen como blanco a hgf.
KR102099462B1 (ko)	2010-11-30	2020-04-10	제넨테크, 인크.	저친화도 혈액-뇌 장벽 수용체 항체 및 그의 용도
SG190885A1 (en)	2010-12-16	2013-07-31	Genentech Inc	Diagnosis and treatments relating to th2 inhibition
PE20141114A1 (es)	2010-12-20	2014-09-15	Genentech Inc	Anticuerpos anti-mesotelina e inmunoconjugados
AR084456A1 (es)	2010-12-22	2013-05-15	Genentech Inc	Anticuerpo anti-pcsk9 y metodos de uso
WO2012092539A2 (en)	2010-12-31	2012-07-05	Takeda Pharmaceutical Company Limited	Antibodies to dll4 and uses thereof
EP2482074A1 (en) *	2011-01-27	2012-08-01	Medizinische Hochschule Hannover	Methods and means for diagnosing vasculitis
RS62238B1 (sr)	2011-02-10	2021-09-30	Roche Glycart Ag	Mutantni interleukin-2 polipeptidi
KR20130118941A (ko)	2011-02-10	2013-10-30	로슈 글리카트 아게	면역치료법
KR101572338B1 (ko)	2011-02-28	2015-11-26	에프. 호프만-라 로슈 아게	1가 항원 결합 단백질
KR101638224B1 (ko)	2011-02-28	2016-07-08	에프. 호프만-라 로슈 아게	항원 결합 단백질
KR101981342B1 (ko)	2011-03-02	2019-05-22	로슈 글리카트 아게	Cea 항체
EP2694551A1 (en)	2011-04-07	2014-02-12	Genentech, Inc.	Anti-fgfr4 antibodies and methods of use
WO2012149197A2 (en)	2011-04-27	2012-11-01	Abbott Laboratories	Methods for controlling the galactosylation profile of recombinantly-expressed proteins
EA201892619A1 (ru)	2011-04-29	2019-04-30	Роше Гликарт Аг	Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
WO2012146630A1 (en)	2011-04-29	2012-11-01	F. Hoffmann-La Roche Ag	N-terminal acylated polypeptides, methods for their production and uses thereof
KR101992502B1 (ko)	2011-05-12	2019-06-24	제넨테크, 인크.	프레임워크 시그너처 펩티드를 사용하여 동물 샘플에서 치료 항체를 검출하기 위한 다중 반응 모니터링 lc-ms/ms 방법
MX339662B (es)	2011-05-16	2016-06-03	Genentech Inc	Antagonistas de fgfr1 y sus metodos de uso.
FI3415531T3 (fi)	2011-05-27	2023-09-07	Glaxo Group Ltd	Bcma:aa (cd269/tnfrsf17) sitovia proteiineja
CA2837914A1 (en)	2011-06-15	2012-12-20	F. Hoffmann-La Roche Ag	Anti-human epo receptor antibodies and methods of use
CN103649125A (zh)	2011-06-22	2014-03-19	霍夫曼-拉罗奇有限公司	利用包含mhc i类的复合物通过循环中的病毒特异性细胞毒性t细胞清除靶细胞
KR20140045440A (ko)	2011-06-30	2014-04-16	제넨테크, 인크.	항-c-met 항체 제제
US20130022551A1 (en)	2011-07-22	2013-01-24	Trustees Of Boston University	DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS
US9499612B2 (en)	2011-07-27	2016-11-22	Glaxo Group Limited	Antigen binding constructs
WO2013025853A1 (en)	2011-08-17	2013-02-21	Genentech, Inc.	Neuregulin antibodies and uses thereof
MX2014001736A (es)	2011-08-17	2014-03-31	Genentech Inc	Inhibicion de angiogenesis en tumores refractarios.
US20130058937A1 (en)	2011-08-23	2013-03-07	Johannes Auer	Bispecific antigen binding molecules
EP2748195A1 (en)	2011-08-23	2014-07-02	Roche Glycart AG	Anti-mcsp antibodies
CA2846083A1 (en)	2011-09-15	2013-03-21	Genentech, Inc.	Methods of promoting differentiation
SG11201400724SA (en)	2011-09-19	2014-04-28	Genentech Inc	Combination treatments comprising c-met antagonists and b-raf antagonists
BR112014008212A2 (pt)	2011-10-05	2017-06-13	Genentech Inc	método para tratar uma condição hepática, método de indução por diferenciação hepática e método de redução de proliferação anormal do ducto biliar
US9738727B2 (en)	2011-10-14	2017-08-22	Genentech, Inc.	Anti-HtrA1 antibodies and methods of use
WO2013057078A1 (en)	2011-10-19	2013-04-25	Roche Glycart Ag	Separation method for fucosylated antibodies
WO2013059531A1 (en)	2011-10-20	2013-04-25	Genentech, Inc.	Anti-gcgr antibodies and uses thereof
MX2014004991A (es)	2011-10-28	2014-05-22	Genentech Inc	Combinaciones terapeuticas y metodos para tratar el melanoma.
AR088920A1 (es)	2011-11-21	2014-07-16	Genentech Inc	Purificacion de anticuerpos anti-c-met
EP2788024A1 (en)	2011-12-06	2014-10-15	F.Hoffmann-La Roche Ag	Antibody formulation
KR20140100571A (ko)	2011-12-08	2014-08-14	바이오테스트 아게	Ｃｄ１３８을 타겟팅하는 면역접합체의 용도
EP2794662A1 (en)	2011-12-22	2014-10-29	F.Hoffmann-La Roche Ag	Full length antibody display system for eukaryotic cells and its use
CA2854249C (en)	2011-12-22	2022-05-03	F. Hoffmann-La Roche Ag	Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides
CA3125875A1 (en)	2011-12-22	2013-06-27	F.Hoffmann-La Roche Ag	Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides
WO2013096791A1 (en)	2011-12-23	2013-06-27	Genentech, Inc.	Process for making high concentration protein formulations
WO2013101771A2 (en)	2011-12-30	2013-07-04	Genentech, Inc.	Compositions and method for treating autoimmune diseases
US20150011431A1 (en)	2012-01-09	2015-01-08	The Scripps Research Institute	Humanized antibodies
US20140050720A1 (en)	2012-01-09	2014-02-20	The Scripps Research Institute	Ultralong complementarity determining regions and uses thereof
KR20140119114A (ko)	2012-01-18	2014-10-08	제넨테크, 인크.	Fgf19 조절제의 사용 방법
IN2014DN05885A (no)	2012-01-18	2015-06-05	Hoffmann La Roche
WO2013113641A1 (en)	2012-01-31	2013-08-08	Roche Glycart Ag	Use of nkp46 as a predictive biomarker for cancer treatment with adcc- enhanced antibodies
MX366804B (es)	2012-02-11	2019-07-25	Genentech Inc	Translocaciones de la r-espondina y sus metodos de uso.
US20150018241A1 (en)	2012-02-15	2015-01-15	Hoffmann-La Roche Inc.	Fc-receptor based affinity chromatography
BR112014018374A8 (pt)	2012-03-02	2017-07-11	Roche Glycart Ag	Método para predizer a resposta d eum paciente com câncer, kit, anticorpo, método para o tratamento do câncer e composição farmacêutica
JP2015514710A (ja)	2012-03-27	2015-05-21	ジェネンテック，インコーポレイテッド	Ｈｅｒ３阻害剤に関する診断及び治療
AR090549A1 (es)	2012-03-30	2014-11-19	Genentech Inc	Anticuerpos anti-lgr5 e inmunoconjugados
US10130714B2 (en)	2012-04-14	2018-11-20	Academia Sinica	Enhanced anti-influenza agents conjugated with anti-inflammatory activity
US9505833B2 (en)	2012-04-20	2016-11-29	Abbvie Inc.	Human antibodies that bind human TNF-alpha and methods of preparing the same
WO2013158279A1 (en)	2012-04-20	2013-10-24	Abbvie Inc.	Protein purification methods to reduce acidic species
US9067990B2 (en)	2013-03-14	2015-06-30	Abbvie, Inc.	Protein purification using displacement chromatography
US9181572B2 (en)	2012-04-20	2015-11-10	Abbvie, Inc.	Methods to modulate lysine variant distribution
BR112014027166A2 (pt)	2012-05-01	2017-06-27	Genentech Inc	anticorpo, ácido nucleico, célula hospedeira, método para produzir um anticorpo, imunoconjugado, formulação farmacêutica, método de tratamento, método de inibir proliferação e métodos de detecção.
WO2013170191A1 (en)	2012-05-11	2013-11-14	Genentech, Inc.	Methods of using antagonists of nad biosynthesis from nicotinamide
TR201810930T4 (tr)	2012-05-18	2018-08-27	Genentech Inc	Yüksek konsantrasyonlu monoklonal antikor formülasyonları.
CN104520325A (zh)	2012-05-21	2015-04-15	霍夫曼-拉罗奇有限公司	用于提高血脑屏障转运的安全性的方法
EP2852610B1 (en)	2012-05-23	2018-07-11	Glykos Finland Oy	Production of fucosylated glycoproteins
RU2625771C2 (ru)	2012-05-23	2017-07-18	Дженентек, Инк.	Способ отбора терапевтических средств
US9249182B2 (en)	2012-05-24	2016-02-02	Abbvie, Inc.	Purification of antibodies using hydrophobic interaction chromatography
CN103463633B (zh) *	2012-06-07	2016-03-30	复旦大学	一种靶向的嵌合乙肝核心抗原治疗性疫苗及其用途
AR091462A1 (es)	2012-06-15	2015-02-04	Genentech Inc	Anticuerpos anti-pcsk9, formulaciones, dosificacion y metodos de uso
WO2014004549A2 (en)	2012-06-27	2014-01-03	Amgen Inc.	Anti-mesothelin binding proteins
RU2630296C2 (ru)	2012-07-04	2017-09-06	Ф. Хоффманн-Ля Рош Аг	Антитела к биотину и способы их применения
SI2869848T1 (sl)	2012-07-04	2017-01-31	F. Hoffmann-La Roche Ag	Kovalentno vezani konjugati antigen-protitelo
WO2014006118A1 (en)	2012-07-04	2014-01-09	F. Hoffmann-La Roche Ag	Anti-theophylline antibodies and methods of use
CN110042114B (zh)	2012-07-05	2024-09-10	弗·哈夫曼-拉罗切有限公司	表达和分泌系统
JP2015527318A (ja)	2012-07-09	2015-09-17	ジェネンテック，インコーポレイテッド	抗ｃｄ２２を含む免疫複合体
EA201590171A1 (ru)	2012-07-09	2015-09-30	Дженентек, Инк.	ИММУНОКОНЪЮГАТЫ, СОДЕРЖАЩИЕ АНТИТЕЛА К CD79b
CN104411337A (zh)	2012-07-09	2015-03-11	基因泰克公司	包含抗cd79b抗体的免疫偶联物
CN104428007B (zh)	2012-07-09	2018-03-16	基因泰克公司	包含抗cd22抗体的免疫缀合物
MA37794B1 (fr)	2012-07-13	2017-07-31	Roche Glycart Ag	Anticorps bispécifiques anti-vegf/anti-ang-2 et leur utilisation dans le cadre du traitement de pathologies vasculaires oculaires
BR112015001459B1 (pt)	2012-07-25	2023-02-14	Celldex Therapeutics, Inc	Anticorpo isolado ou fragmento do mesmo, conjugado, usos dos mesmos, composição farmacêutica, polinucleotídeo, vetor, célula hospedeira, célula isolada, kit, método in vitro para inibir atividade da kit, método para produzir um anticorpo
EP2882777B1 (en)	2012-08-07	2018-10-10	Roche Glycart AG	Composition comprising two antibodies engineered to have reduced and increased effector function
WO2014031498A1 (en)	2012-08-18	2014-02-27	Academia Sinica	Cell-permeable probes for identification and imaging of sialidases
AU2013305827A1 (en)	2012-08-21	2015-03-05	Academia Sinica	Benzocyclooctyne compounds and uses thereof
WO2014029752A1 (en)	2012-08-22	2014-02-27	Glaxo Group Limited	Anti lrp6 antibodies
CA2879496C (en)	2012-08-29	2024-01-09	F. Hoffmann-La Roche Ag	Blood brain barrier shuttle
US9512214B2 (en)	2012-09-02	2016-12-06	Abbvie, Inc.	Methods to control protein heterogeneity
BR112015004467A2 (pt)	2012-09-02	2017-03-21	Abbvie Inc	método para controlar a heterogeneidade de proteínas
EP3919079A1 (en)	2012-09-07	2021-12-08	Genentech, Inc.	Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitor
SI2766048T1 (sl)	2012-10-12	2015-03-31	Spirogen Sarl	Pirolobenzodiazepini in njihovi konjugati
EP2912060B1 (en)	2012-10-29	2019-12-25	The University of North Carolina at Chapel Hill	Compositions and methods for inhibiting pathogen infection
AU2013337277B2 (en)	2012-11-05	2018-03-08	Foundation Medicine, Inc.	Novel NTRK1 fusion molecules and uses thereof
EP2917243B1 (en)	2012-11-08	2018-03-14	F.Hoffmann-La Roche Ag	Her3 antigen binding proteins binding to the beta-hairpin of her3
KR20150083124A (ko)	2012-11-13	2015-07-16	제넨테크, 인크.	항-헤마글루티닌 항체 및 사용 방법
CN104884474A (zh)	2012-12-21	2015-09-02	弗·哈夫曼-拉罗切有限公司	包含i类mhc的二硫键连接多价多功能蛋白质
AU2014207342C1 (en)	2013-01-18	2019-04-04	Foundation Medicine, Inc.	Methods of treating cholangiocarcinoma
WO2014116749A1 (en)	2013-01-23	2014-07-31	Genentech, Inc.	Anti-hcv antibodies and methods of using thereof
WO2014114595A1 (en)	2013-01-23	2014-07-31	Roche Glycart Ag	Predictive biomarker for cancer treatment with adcc-enhanced antibodies
BR112015019348A2 (pt)	2013-02-13	2017-08-22	Lab Francais Du Fractionnement	Métodos para produção de proteína com glicosilação modificada e com sialilação aumentada, para aumentar a atividade de sialil transferase na glândula mamária e para produzir sialil transferase, proteína com glicosilação modificada ou proteína com sialilação aumentada, composição, sialil transferase, mamífero transgênico, e, célula epitelial mamária
AU2014217561B2 (en)	2013-02-13	2018-11-15	Laboratoire Francais Du Fractionnement Et Des Biotechnologies	Highly galactosylated anti-TNF-alpha antibodies and uses thereof
CA2900097A1 (en)	2013-02-22	2014-08-28	F. Hoffmann-La Roche Ag	Methods of treating cancer and preventing drug resistance
US20140242083A1 (en)	2013-02-26	2014-08-28	Roche Glycart Ag	Anti-mcsp antibodies
JP2016510751A (ja)	2013-03-06	2016-04-11	ジェネンテック，インコーポレイテッド	抗がん剤耐性を治療及び予防する方法
ES2687439T3 (es)	2013-03-13	2018-10-25	Medimmune Limited	Pirrolobenzodiazepinas y conjugados de las mismas
CA2905070A1 (en)	2013-03-14	2014-09-25	Genentech, Inc.	Methods of treating cancer and preventing cancer drug resistance
MX2015010777A (es)	2013-03-14	2016-04-25	Genentech Inc	Anticuerpos e inmunoconjugados anti-b7-h4.
US9017687B1 (en)	2013-10-18	2015-04-28	Abbvie, Inc.	Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en)	2013-03-14	2014-09-25	Abbvie Inc.	Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
WO2014152358A2 (en)	2013-03-14	2014-09-25	Genentech, Inc.	Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use
US9562099B2 (en)	2013-03-14	2017-02-07	Genentech, Inc.	Anti-B7-H4 antibodies and immunoconjugates
US8921526B2 (en)	2013-03-14	2014-12-30	Abbvie, Inc.	Mutated anti-TNFα antibodies and methods of their use
WO2014144850A1 (en)	2013-03-15	2014-09-18	Genentech, Inc.	Methods of treating cancer and preventing cancer drug resistance
EP3385277A1 (en)	2013-03-15	2018-10-10	F. Hoffmann-La Roche AG	Il-22 polypeptides and il-22 fc fusion proteins and methods of use
SG11201507427QA (en)	2013-03-15	2015-10-29	Genentech Inc	Compositions and methods for diagnosis and treatment of hepatic cancers
WO2014144865A2 (en)	2013-03-15	2014-09-18	Genentech, Inc.	Anti-crth2 antibodies and methods of use
KR102389677B1 (ko)	2013-03-15	2022-04-21	제넨테크, 인크.	Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법
IL240838B (en)	2013-03-15	2022-09-01	Glaxosmithkline Ip Dev Ltd	Anti-3–lag binding proteins
KR102233349B1 (ko)	2013-03-15	2021-03-31	에이씨 이뮨 에스.에이.	항-타우(tau) 항체 및 사용 방법
UA118028C2 (uk)	2013-04-03	2018-11-12	Рош Глікарт Аг	Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
EP3327034A1 (en)	2013-04-29	2018-05-30	F. Hoffmann-La Roche AG	Fcrn-binding abolished anti-igf-1r antibodies and their use in the treatment of vascular eye diseases
EP3878866A1 (en)	2013-04-29	2021-09-15	F. Hoffmann-La Roche AG	Fc-receptor binding modified asymmetric antibodies and methods of use
SG11201508911PA (en)	2013-04-29	2015-11-27	Hoffmann La Roche	Human fcrn-binding modified antibodies and methods of use
EP3594240B1 (en)	2013-05-20	2023-12-06	F. Hoffmann-La Roche AG	Anti-transferrin receptor antibodies and methods of use
US10086054B2 (en)	2013-06-26	2018-10-02	Academia Sinica	RM2 antigens and use thereof
EP3013347B1 (en)	2013-06-27	2019-12-11	Academia Sinica	Glycan conjugates and use thereof
US20160168231A1 (en)	2013-07-18	2016-06-16	Fabrus, Inc.	Antibodies with ultralong complementarity determining regions
AU2014290361B2 (en)	2013-07-18	2019-04-18	Taurus Biosciences, Llc	Humanized antibodies with ultralong complementarity determining regions
CA2915665C (en)	2013-08-01	2020-07-28	Five Prime Therapeutics, Inc.	Afucosylated anti-fgfr2iiib antibodies
PE20160192A1 (es)	2013-08-12	2016-04-27	Genentech Inc	Composiciones y metodo para tratar condiciones asociadas con el complemento
EP3041484B1 (en)	2013-09-06	2021-03-03	Academia Sinica	Human inkt cell activation using glycolipids with altered glycosyl groups
CN105518027A (zh)	2013-09-17	2016-04-20	豪夫迈·罗氏有限公司	使用抗lgr5抗体的方法
WO2015051293A2 (en)	2013-10-04	2015-04-09	Abbvie, Inc.	Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
EP3620470B1 (en)	2013-10-11	2023-07-26	The United States of America, as represented by The Secretary, Department of Health and Human Services	Tem8 antibodies and their use
CN105612182B (zh)	2013-10-11	2019-12-10	豪夫迈·罗氏有限公司	多特异性结构域交换共有可变轻链抗体
MX2016004573A (es)	2013-10-11	2016-07-21	Genentech Inc	Inhibidores de nsp4 y metodos de uso.
US9085618B2 (en)	2013-10-18	2015-07-21	Abbvie, Inc.	Low acidic species compositions and methods for producing and using the same
US9181337B2 (en)	2013-10-18	2015-11-10	Abbvie, Inc.	Modulated lysine variant species compositions and methods for producing and using the same
BR112016008477A2 (pt)	2013-10-18	2017-10-03	Genentech Inc	Corpos, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica e usos do anticorpo
US8946395B1 (en)	2013-10-18	2015-02-03	Abbvie Inc.	Purification of proteins using hydrophobic interaction chromatography
RU2016119425A (ru)	2013-10-23	2017-11-28	Дженентек, Инк.	Способы диагностики и лечения эозинофильных заболеваний
US20150139988A1 (en)	2013-11-15	2015-05-21	Abbvie, Inc.	Glycoengineered binding protein compositions
CN105722857B (zh)	2013-11-21	2023-03-24	豪夫迈·罗氏有限公司	抗-α-突触核蛋白抗体及使用方法
WO2015089117A1 (en)	2013-12-09	2015-06-18	Allakos Inc.	Anti-siglec-8 antibodies and methods of use thereof
US20160333063A1 (en)	2013-12-13	2016-11-17	The General Hospital Corporation	Soluble high molecular weight (hmw) tau species and applications thereof
EP3461845B1 (en)	2013-12-13	2020-09-16	Genentech, Inc.	Anti-cd33 antibodies and immunoconjugates
HUE047699T2 (hu)	2013-12-17	2020-05-28	Hoffmann La Roche	Eljárások rákbetegségek kezelésére PD-1-tengelyhez kötõdõ antagonisták és taxánok alkalmazásával
TWI701261B (zh)	2013-12-17	2020-08-11	美商建南德克公司	抗cd3抗體及使用方法
EP3527587A1 (en)	2013-12-17	2019-08-21	F. Hoffmann-La Roche AG	Combination therapy comprising ox40 binding agonists and pd-l1 binding antagonists
MX2016007885A (es)	2013-12-17	2017-01-11	Genentech Inc	Metodos de tratamiento de cancer usando antagonistas de union del eje de pd-1 y un anticuerpo anti-cd20.
TWI728373B (zh)	2013-12-23	2021-05-21	美商建南德克公司	抗體及使用方法
PL3087095T3 (pl)	2013-12-24	2020-03-31	Argenx Bvba	Antagoniści fcrn i sposoby stosowania
EP3089759B1 (en)	2014-01-03	2018-12-05	F. Hoffmann-La Roche AG	Covalently linked polypeptide toxin-antibody conjugates
KR102278979B1 (ko)	2014-01-03	2021-07-19	에프. 호프만-라 로슈 아게	공유적으로 연결된 헬리카-항-헬리카 항체 접합체 및 그의 용도
PL3089996T3 (pl)	2014-01-03	2021-12-13	F. Hoffmann-La Roche Ag	Dwuswoiste przeciwciała przeciw haptenowi/przeciw receptorowi występującemu w barierze krew-mózg, ich kompleksy i ich zastosowanie jako przenośniki wahadłowe występujące w barierze krew-mózg
WO2015103549A1 (en)	2014-01-03	2015-07-09	The United States Of America, As Represented By The Secretary Department Of Health And Human Services	Neutralizing antibodies to hiv-1 env and their use
WO2015101588A1 (en)	2014-01-06	2015-07-09	F. Hoffmann-La Roche Ag	Monovalent blood brain barrier shuttle modules
JP6786392B2 (ja)	2014-01-15	2020-11-18	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	ＦｃＲｎ結合特性が改変され、プロテインＡ結合特性が保持されているＦｃ領域変異体
CN106459920B (zh)	2014-01-16	2020-10-30	中央研究院	治疗及检测癌症的组合物及方法
US10150818B2 (en)	2014-01-16	2018-12-11	Academia Sinica	Compositions and methods for treatment and detection of cancers
US10023892B2 (en)	2014-05-27	2018-07-17	Academia Sinica	Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
AU2015209154A1 (en)	2014-01-24	2017-02-16	Genentech, Inc.	Methods of using anti-STEAP1 antibodies and immunoconjugates
CA2937539A1 (en)	2014-02-04	2015-08-13	Genentech, Inc.	Mutant smoothened and methods of using the same
TWI769970B (zh)	2014-02-08	2022-07-11	美商建南德克公司	治療阿茲海默症之方法
AU2015214058B2 (en)	2014-02-08	2020-07-09	Genentech, Inc.	Methods of treating Alzheimer's Disease
SI3105253T1 (sl)	2014-02-12	2018-10-30	F. Hoffmann-La Roche Ag	Protitelesa anti-Jagged1 in načini njihove uporabe
MX2016010729A (es)	2014-02-21	2016-10-26	Genentech Inc	Anticuerpos biespecificos anti-il-13 / il-17 y sus usos.
EP4014995A1 (en)	2014-02-28	2022-06-22	Allakos Inc.	Methods and compositions for treating siglec-8 associated diseases
AU2015229035B2 (en)	2014-03-14	2021-08-05	Genentech, Inc.	Methods and compositions for secretion of heterologous polypeptides
US20170107294A1 (en)	2014-03-21	2017-04-20	Nordlandssykehuset Hf	Anti-cd14 antibodies and uses thereof
KR20160137599A (ko)	2014-03-24	2016-11-30	제넨테크, 인크.	C-met 길항제로의 암 치료 및 이것과 hgf 발현과의 상관관계
TWI687428B (zh)	2014-03-27	2020-03-11	中央研究院	反應性標記化合物及其用途
ES2763898T3 (es)	2014-03-31	2020-06-01	Hoffmann La Roche	Anticuerpos anti-OX40 y procedimientos de uso
JP6588461B2 (ja)	2014-03-31	2019-10-09	ジェネンテック，インコーポレイテッド	抗血管新生剤及びｏｘ４０結合アゴニストを含む併用療法
WO2015164615A1 (en)	2014-04-24	2015-10-29	University Of Oslo	Anti-gluten antibodies and uses thereof
CN106414499A (zh)	2014-05-22	2017-02-15	基因泰克公司	抗gpc3抗体和免疫偶联物
CN106661622B (zh)	2014-05-23	2020-08-21	豪夫迈·罗氏有限公司	Mit生物标志物和使用它们的方法
US10118969B2 (en)	2014-05-27	2018-11-06	Academia Sinica	Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
US10005847B2 (en)	2014-05-27	2018-06-26	Academia Sinica	Anti-HER2 glycoantibodies and uses thereof
KR20220151036A (ko)	2014-05-27	2022-11-11	아카데미아 시니카	항-ｃｄ20 글리코항체 및 이의 용도
TWI732738B (zh)	2014-05-28	2021-07-11	中央研究院	抗TNF-α醣抗體及其用途
CA2949982A1 (en)	2014-06-11	2015-12-17	Genentech, Inc.	Anti-lgr5 antibodies and uses thereof
EP3154589A1 (en)	2014-06-13	2017-04-19	Genentech, Inc.	Methods of treating and preventing cancer drug resistance
CA2947504A1 (en)	2014-06-26	2015-12-30	F. Hoffmann-La Roche Ag	Anti-brdu antibodies and methods of use
JP7032929B2 (ja)	2014-07-11	2022-03-09	ヴェンタナメディカルシステムズ，インク．	抗ｐｄ－ｌ１抗体及びその診断上の使用
JP2017526641A (ja)	2014-07-11	2017-09-14	ジェネンテック，インコーポレイテッド	Ｎｏｔｃｈ経路阻害
CA2954974A1 (en)	2014-07-21	2016-01-28	Glykos Finland Oy	Production of glycoproteins with mammalian-like n-glycans in filamentous fungi
MA40475A (fr)	2014-08-19	2017-06-28	Fayadat Dilman Laurence	Anticorps anti-tigit
TWI751102B (zh)	2014-08-28	2022-01-01	美商奇諾治療有限公司	對ｃｄ１９具專一性之抗體及嵌合抗原受體
US20170260261A1 (en)	2014-08-28	2017-09-14	Bioatla, Llc	Conditionally Active Chimeric Antigen Receptors for Modified T-Cells
CA2960712A1 (en)	2014-09-08	2016-03-17	Academia Sinica	Human inkt cell activation using glycolipids
US10188746B2 (en)	2014-09-10	2019-01-29	Medimmune Limited	Pyrrolobenzodiazepines and conjugates thereof
AU2015314954B2 (en)	2014-09-12	2021-05-13	Genentech, Inc.	Anti-HER2 antibodies and immunoconjugates
SG11201701627PA (en)	2014-09-12	2017-03-30	Genentech Inc	Anti-cll-1 antibodies and immunoconjugates
EP3191518B1 (en)	2014-09-12	2020-01-15	Genentech, Inc.	Anti-b7-h4 antibodies and immunoconjugates
KR20170055521A (ko)	2014-09-17	2017-05-19	제넨테크, 인크.	항-her2 항체를 포함하는 면역콘주게이트
ES2796903T3 (es)	2014-09-23	2020-11-30	Hoffmann La Roche	Procedimiento de uso de inmunoconjugados anti-CD79b
MA40764A (fr)	2014-09-26	2017-08-01	Chugai Pharmaceutical Co Ltd	Agent thérapeutique induisant une cytotoxicité
WO2016059602A2 (en)	2014-10-16	2016-04-21	Glaxo Group Limited	Methods of treating cancer and related compositions
US9732148B2 (en)	2014-10-16	2017-08-15	Genentech, Inc.	Anti-α-synuclein antibodies and methods of use
WO2016070001A1 (en)	2014-10-31	2016-05-06	Jounce Therapeutics, Inc.	Methods of treating conditions with antibodies that bind b7-h4
EP3215637B1 (en)	2014-11-03	2019-07-03	F. Hoffmann-La Roche AG	Methods and biomarkers for predicting efficacy and valuation of an ox40 agonist treatment
SG11201703448QA (en)	2014-11-03	2017-05-30	Genentech Inc	Assays for detecting t cell immune subsets and methods of use thereof
MX2017003478A (es)	2014-11-05	2018-02-01	Genentech Inc	Anticuerpos anti-fgfr2/3 y metodos para su uso.
MX2017005929A (es)	2014-11-06	2017-11-20	Genentech Inc	Terapia de combinacion con agonistas de unión ox40 e inhibidores de tigit.
KR20170076697A (ko)	2014-11-06	2017-07-04	에프. 호프만-라 로슈 아게	개질된 FCRN-결합 특성 및 단백질 A-결합 특성을 가진 Fc-영역 변이체
AR102521A1 (es)	2014-11-06	2017-03-08	Hoffmann La Roche	Variantes de región fc con unión de fcrn modificada y métodos de utilización
JP2018500882A (ja)	2014-11-10	2018-01-18	ジェネンテック，インコーポレイテッド	腎症の動物モデルおよびそれを治療するための薬剤
US10093730B2 (en)	2014-11-10	2018-10-09	Genentech, Inc.	Anti-interleukin-33 antibodies and uses thereof
EP3875481A1 (en)	2014-11-14	2021-09-08	The U.S.A. as represented by the Secretary, Department of Health and Human Services	Neutralizing antibodies to ebola virus glycoprotein and their use
CR20170194A (es)	2014-11-14	2017-07-10	Hoffmann La Roche	Moleculas de unión a antígeno que comprenden un trímero de ligando de la familia de tnf
BR112017010198A2 (pt)	2014-11-17	2017-12-26	Genentech Inc	terapia de combinação compreendendo agonistas de ligação a ox40 e antagonistas de ligação ao eixo de pd-1
EP3221362B1 (en)	2014-11-19	2019-07-24	F.Hoffmann-La Roche Ag	Anti-transferrin receptor antibodies and methods of use
JP6859259B2 (ja)	2014-11-19	2021-04-14	ジェネンテック，インコーポレイテッド	ＢＡＣＥｌに対する抗体及び神経疾患免疫療法のためのその使用
CN107250158B (zh)	2014-11-19	2022-03-25	基因泰克公司	抗转铁蛋白受体/抗bace1多特异性抗体和使用方法
SI3221349T1 (sl)	2014-11-19	2021-02-26	Axon Neuroscience Se	Humanizirano tau protitelo pri alzheimerjevi bolezni
MX2017006610A (es)	2014-11-20	2017-09-29	Hoffmann La Roche	Terapia combinada de moleculas de union a antigeno biespecificas activadoras de celulas t y antagonistas de union de eje de pd-1.
PL3227332T3 (pl)	2014-12-03	2020-06-15	F. Hoffmann-La Roche Ag	Wielospecyficzne przeciwciała
TWI713480B (zh)	2014-12-05	2020-12-21	美商建南德克公司	抗ＣＤ７９ｂ抗體及其使用方法
KR20170085595A (ko)	2014-12-10	2017-07-24	제넨테크, 인크.	혈뇌 장벽 수용체 항체 및 사용 방법
HUE056489T2 (hu)	2014-12-19	2022-02-28	Chugai Pharmaceutical Co Ltd	Anti-C5 antitestek és alkalmazási eljárások
MY181199A (en)	2014-12-19	2020-12-21	Chugai Pharmaceutical Co Ltd	Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
WO2016111947A2 (en)	2015-01-05	2016-07-14	Jounce Therapeutics, Inc.	Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
US10495645B2 (en)	2015-01-16	2019-12-03	Academia Sinica	Cancer markers and methods of use thereof
US20160208018A1 (en)	2015-01-16	2016-07-21	Juno Therapeutics, Inc.	Antibodies and chimeric antigen receptors specific for ror1
US9975965B2 (en)	2015-01-16	2018-05-22	Academia Sinica	Compositions and methods for treatment and detection of cancers
US20180016327A1 (en)	2015-01-22	2018-01-18	Chugai Seiyaku Kabushiki Kaisha	A Combination of Two or More Anti-C5 Antibodies and Methods of Use
WO2016118191A1 (en)	2015-01-24	2016-07-28	Academia Sinica	Novel glycan conjugates and methods of use thereof
JP2018506275A (ja)	2015-01-28	2018-03-08	ジェネンテック，インコーポレイテッド	多発性硬化症の遺伝子発現マーカー及び治療
CA2975875A1 (en)	2015-02-04	2016-08-11	Genentech, Inc.	Mutant smoothened and methods of using the same
EA201791754A1 (ru)	2015-02-05	2019-01-31	Чугаи Сейяку Кабусики Кайся	АНТИТЕЛА, СОДЕРЖАЩИЕ ЗАВИСЯЩИЙ ОТ КОНЦЕНТРАЦИИ ИОНОВ АНТИГЕНСВЯЗЫВАЮЩИЙ ДОМЕН, ВАРИАНТЫ Fc-ОБЛАСТИ, IL-8-СВЯЗЫВАЮЩИЕ АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ
WO2016138160A1 (en)	2015-02-24	2016-09-01	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
DK3268391T3 (da)	2015-03-09	2021-09-13	Argenx Bvba	Fremgangsmåder til reduktion af serumniveauer af Fc-indeholdende midler ved anvendelse af FcRn-antagonister
CA2977285A1 (en)	2015-03-16	2016-09-22	F. Hoffmann-La Roche Ag	Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases
WO2016146833A1 (en)	2015-03-19	2016-09-22	F. Hoffmann-La Roche Ag	Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
RS60270B1 (sr)	2015-03-20	2020-06-30	The United States Of America As Represented By The Secretary Department Of Health And Human Services	Neutralizacija antitela do gp120 i njihova upotreba
MX2017012278A (es)	2015-03-23	2018-05-23	Bayer Pharma AG	Anticuerpos anti-ceacam6 y sus usos.
RS60614B1 (sr)	2015-03-23	2020-08-31	Jounce Therapeutics Inc	Antitela za icos
AU2016243026B2 (en)	2015-04-03	2022-03-31	Eureka Therapeutics, Inc.	Constructs targeting AFP peptide/MHC complexes and uses thereof
ES2881694T3 (es)	2015-04-24	2021-11-30	Hoffmann La Roche	Procedimientos de identificación de bacterias que comprenden polipéptidos de unión
EP3288981A1 (en)	2015-05-01	2018-03-07	Genentech, Inc.	Masked anti-cd3 antibodies and methods of use
WO2016179194A1 (en)	2015-05-04	2016-11-10	Jounce Therapeutics, Inc.	Lilra3 and method of using the same
CN108137686B (zh)	2015-05-07	2022-06-17	阿吉纳斯公司	抗ox40抗体及其使用方法
JP6963508B2 (ja)	2015-05-11	2021-11-10	ジェネンテック，インコーポレイテッド	ループス腎炎を治療する組成物及び方法
IL255312B (en)	2015-05-12	2022-08-01	Genentech Inc	Therapeutic and diagnostic methods for cancer containing a pd–l1 binding antagonist
EP3303632B2 (en)	2015-05-29	2023-05-10	F. Hoffmann-La Roche AG	Therapeutic and diagnostic methods for cancer
JP6884111B2 (ja)	2015-05-29	2021-06-09	ジェネンテック，インコーポレイテッド	癌におけるｐｄ−ｌ１プロモーターのメチル化
EP3302563A1 (en)	2015-05-29	2018-04-11	H. Hoffnabb-La Roche Ag	Humanized anti-ebola virus glycoprotein antibodies and methods of use
JP2018516933A (ja)	2015-06-02	2018-06-28	ジェネンテック，インコーポレイテッド	抗ｉｌ−３４抗体を使用して神経学的疾患を治療するための組成物及び方法
WO2016196975A1 (en)	2015-06-03	2016-12-08	The United States Of America, As Represented By The Secretary Department Of Health & Human Services	Neutralizing antibodies to hiv-1 env and their use
EA201792669A1 (ru)	2015-06-04	2018-06-29	Оспедале Сан Раффаэле Срл	Igfbp3 и его применение
US20180169184A1 (en)	2015-06-04	2018-06-21	Ospedale San Raffaele Srl	Inhibitor of IGFBP3/TMEM219 Axis and Diabetes
PE20180317A1 (es)	2015-06-05	2018-02-09	Genentech Inc	Anticuerpos anti-tau y metodos de uso
AU2016274584A1 (en)	2015-06-08	2018-01-04	Genentech, Inc.	Methods of treating cancer using anti-OX40 antibodies and PD-1 axis binding antagonists
KR20180011839A (ko)	2015-06-08	2018-02-02	제넨테크, 인크.	항-ox40 항체를 이용한 암의 치료 방법
US10017577B2 (en)	2015-06-15	2018-07-10	Genentech, Inc.	Antibodies and immunoconjugates
JP2018526972A (ja)	2015-06-16	2018-09-20	ジェネンテック，インコーポレイテッド	抗ｃｄ３抗体及び使用方法
KR20180023952A (ko)	2015-06-16	2018-03-07	제넨테크, 인크.	FcRH5에 대한 인간화 및 친화도 성숙 항체 및 사용방법
JP6996983B2 (ja)	2015-06-16	2022-02-21	ジェネンテック，インコーポレイテッド	抗ｃｌｌ－１抗体及び使用方法
MX2017016169A (es)	2015-06-17	2018-08-15	Genentech Inc	Anticuerpos anti-her2 y metodos de uso.
CA2987797A1 (en)	2015-06-17	2016-12-22	Christopher Robert Bebbington	Methods and compositions for treating fibrotic diseases
EP3310815A1 (en)	2015-06-17	2018-04-25	F. Hoffmann-La Roche AG	Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
MY180297A (en)	2015-06-24	2020-11-27	Hoffmann La Roche	Anti-transferrin receptor antibodies with tailored affinity
EP3313885A1 (en)	2015-06-29	2018-05-02	H. Hoffnabb-La Roche Ag	Type ii anti-cd20 antibody for use in organ transplantation
CA2990214A1 (en)	2015-06-29	2017-01-05	Spring Bioscience Corporation	Materials and methods for performing histochemical assays for human pro-epiregulin and amphiregulin
RU2611685C2 (ru) *	2015-07-20	2017-02-28	Илья Владимирович Духовлинов	Гуманизированное моноклональное антитело, специфичное к синдекану-1
EP4137158A1 (en)	2015-08-07	2023-02-22	Imaginab, Inc.	Antigen binding constructs to target molecules
CN105384825B (zh)	2015-08-11	2018-06-01	南京传奇生物科技有限公司	一种基于单域抗体的双特异性嵌合抗原受体及其应用
JP6914919B2 (ja)	2015-08-28	2021-08-04	ジェネンテック，インコーポレイテッド	抗ヒプシン抗体及びその使用
KR20180042412A (ko)	2015-09-02	2018-04-25	이뮤텝 에스.에이.에스.	항-lag-3 항체
AU2016328357B2 (en)	2015-09-22	2023-03-02	Ventana Medical Systems, Inc.	Anti-OX40 antibodies and diagnostic uses thereof
AU2016326666B2 (en)	2015-09-23	2023-06-15	Genentech, Inc.	Optimized variants of anti-VEGF antibodies
CA2999917A1 (en)	2015-09-24	2017-03-30	Abvitro Llc	Hiv antibody compositions and methods of use
WO2017053748A2 (en)	2015-09-25	2017-03-30	Genentech, Inc.	Anti-tigit antibodies and methods of use
EP4435105A2 (en)	2015-09-29	2024-09-25	Amgen Inc.	Asgr inhibitors for reduzing cholesterol levels
AR106188A1 (es)	2015-10-01	2017-12-20	Hoffmann La Roche	Anticuerpos anti-cd19 humano humanizados y métodos de utilización
CR20180161A (es)	2015-10-02	2018-05-25	Hoffmann La Roche	Anticuerpos biespecíficos para pd1 y tim3
KR20180053674A (ko)	2015-10-02	2018-05-23	에프. 호프만-라 로슈 아게	공자극 tnf 수용체에 특이적인 이중특이성 항체
EP3150636A1 (en)	2015-10-02	2017-04-05	F. Hoffmann-La Roche AG	Tetravalent multispecific antibodies
AR106189A1 (es)	2015-10-02	2017-12-20	Hoffmann La Roche	ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
MA43345A (fr)	2015-10-02	2018-08-08	Hoffmann La Roche	Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
RU2753390C1 (ru)	2015-10-02	2021-08-13	Ф. Хоффманн-Ля Рош Аг	Биспецифические антитела к человеческому cd20/человеческому рецептору трансферрина и способы их применения
KR20240107346A (ko)	2015-10-06	2024-07-09	제넨테크, 인크.	다발성 경화증을 치료하기 위한 방법
AU2016335750B2 (en)	2015-10-07	2023-05-25	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	IL-7R-alpha specific antibodies for treating acute lymphoblastic leukemia
MX2018004157A (es)	2015-10-07	2019-04-01	F Hoffmann La Roche Ag	Anticuerpos biespecificos con tetravalencia para un receptor de fnt coestimulador.
CA2998208A1 (en)	2015-10-22	2017-04-27	Jounce Therapeutics, Inc.	Gene signatures for determining icos expression
US10604577B2 (en)	2015-10-22	2020-03-31	Allakos Inc.	Methods and compositions for treating systemic mastocytosis
CN114891102A (zh)	2015-10-29	2022-08-12	豪夫迈·罗氏有限公司	抗变体Fc区抗体及使用方法
EP3184547A1 (en)	2015-10-29	2017-06-28	F. Hoffmann-La Roche AG	Anti-tpbg antibodies and methods of use
JO3555B1 (ar)	2015-10-29	2020-07-05	Merck Sharp & Dohme	جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
SI3368578T1 (sl)	2015-10-30	2021-08-31	F. Hoffmann-La Roche Ag	Protitelesa proti HtrA1 in postopki uporabe
CN108289951A (zh)	2015-10-30	2018-07-17	豪夫迈·罗氏有限公司	抗-因子d抗体和缀合物
AU2016349392B2 (en)	2015-11-03	2023-07-13	The Trustees Of Columbia University In The City Of New York	Neutralizing antibodies to HIV-1 gp41 and their use
JP6998869B2 (ja)	2015-11-08	2022-02-04	ジェネンテック，インコーポレイテッド	多重特異性抗体のスクリーニング方法
US11447553B2 (en)	2015-11-23	2022-09-20	Five Prime Therapeutics, Inc.	FGFR2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
JP7325186B2 (ja)	2015-12-09	2023-08-14	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	抗薬物抗体の形成を減少させるためのｉｉ型抗ｃｄ２０抗体
BR112018009067A8 (pt)	2015-12-18	2019-02-26	Chugai Pharmaceutical Co Ltd	anticorpos anti-c5 e métodos de uso
CN108472379B (zh)	2015-12-30	2022-06-21	豪夫迈·罗氏有限公司	减少聚山梨酯降解的制剂
AR107303A1 (es)	2016-01-08	2018-04-18	Hoffmann La Roche	Métodos de tratamiento de cánceres positivos para ace utilizando antagonistas de unión a eje pd-1 y anticuerpos biespecíficos anti-ace / anti-cd3, uso, composición, kit
CN114113625A (zh)	2016-01-20	2022-03-01	基因泰克公司	用于阿尔茨海默氏病的高剂量治疗
RU2018128784A (ru) *	2016-01-27	2020-02-27	МЕДИММЬЮН, ЭлЭлСи	Способы получения антител с заданным профилем гликозилирования
CN109071625A (zh)	2016-02-04	2018-12-21	柯瑞斯公司	平滑化突变体和其使用方法
US10654930B2 (en)	2016-02-25	2020-05-19	B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University	Composition and method for treating amyotrophic lateral sclerosis
AU2017225854B2 (en)	2016-02-29	2020-11-19	Foundation Medicine, Inc.	Therapeutic and diagnostic methods for cancer
CN109195996A (zh)	2016-03-08	2019-01-11	中央研究院	N-聚醣及其阵列的模组化合成方法
TW202248213A (zh)	2016-03-15	2022-12-16	日商中外製藥股份有限公司	使用pd-1軸結合拮抗劑和抗gpc3抗體治療癌症的方法
US20170315132A1 (en)	2016-03-25	2017-11-02	Genentech, Inc.	Multiplexed total antibody and antibody-conjugated drug quantification assay
JP7468992B2 (ja)	2016-03-29	2024-04-16	ヤンセンバイオテツク，インコーポレーテツド	抗ｉｌ１２及び／又は－２３抗体の増加した間隔投与による乾癬の処置
JP2019510786A (ja)	2016-04-05	2019-04-18	グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＤｅｖｅｌｏｐｍｅｎｔＬｉｍｉｔｅｄ	免疫療法におけるＴＧＦβの阻害
EP3443004A1 (en)	2016-04-14	2019-02-20	H. Hoffnabb-La Roche Ag	Anti-rspo3 antibodies and methods of use
EP3443120A2 (en)	2016-04-15	2019-02-20	H. Hoffnabb-La Roche Ag	Methods for monitoring and treating cancer
PL3443350T3 (pl)	2016-04-15	2021-05-31	F. Hoffmann-La Roche Ag	Sposoby monitorowania i leczenia nowotworu
CN109563164A (zh)	2016-04-15	2019-04-02	生物蛋白有限公司	抗axl抗体、抗体片段和它们的免疫缀合物以及其用途
EP3452502B1 (en)	2016-05-02	2021-03-03	H. Hoffnabb-La Roche Ag	The contorsbody - a single chain target binder
WO2017192589A1 (en)	2016-05-02	2017-11-09	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Neutralizing antibodies to influenza ha and their use and identification
EP3243836A1 (en)	2016-05-11	2017-11-15	F. Hoffmann-La Roche AG	C-terminally fused tnf family ligand trimer-containing antigen binding molecules
WO2017194442A1 (en)	2016-05-11	2017-11-16	F. Hoffmann-La Roche Ag	Antigen binding molecules comprising a tnf family ligand trimer and a tenascin binding moiety
EP3455252B1 (en)	2016-05-11	2022-02-23	F. Hoffmann-La Roche AG	Modified anti-tenascin antibodies and methods of use
EP3243832A1 (en)	2016-05-13	2017-11-15	F. Hoffmann-La Roche AG	Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
EP3455261B1 (en)	2016-05-13	2022-08-03	BioAtla, Inc.	Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof
PL3458101T3 (pl)	2016-05-20	2021-05-31	F. Hoffmann-La Roche Ag	Koniugaty PROTAC-przeciwciało i sposoby ich stosowania
JP7022080B2 (ja)	2016-05-27	2022-02-17	ジェネンテック，インコーポレイテッド	部位特異的抗体－薬物複合体の特徴付けのための生化学分析的方法
AU2018276419A1 (en)	2016-06-02	2019-10-17	F. Hoffmann-La Roche Ag	Type II anti-CD20 antibody and anti-CD20/CD3 bispecific antibody for treatment of cancer
EP3252078A1 (en)	2016-06-02	2017-12-06	F. Hoffmann-La Roche AG	Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
EP3475298A1 (en)	2016-06-24	2019-05-01	H. Hoffnabb-La Roche Ag	Anti-polyubiquitin multispecific antibodies
JP6983824B2 (ja)	2016-07-04	2021-12-17	エフ.ホフマン−ラロシュアーゲーF. Hoffmann−La Roche Aktiengesellschaft	新規抗体フォーマット
WO2018014260A1 (en)	2016-07-20	2018-01-25	Nanjing Legend Biotech Co., Ltd.	Multispecific antigen binding proteins and methods of use thereof
CN117903316A (zh)	2016-07-29	2024-04-19	朱诺治疗学股份有限公司	抗独特型抗体及相关方法
EP3492496A4 (en)	2016-07-29	2020-07-29	Chugai Seiyaku Kabushiki Kaisha	BISPECIFIC ANTIBODY WITH INCREASED ACTIVITY OF THE FUNCTION OF THE ALTERNATIVE FVIII COFACTOR
NL2017270B1 (en)	2016-08-02	2018-02-09	Aduro Biotech Holdings Europe B V	New anti-hCTLA-4 antibodies
KR102538749B1 (ko)	2016-08-05	2023-06-01	추가이 세이야쿠 가부시키가이샤	Il-8 관련 질환의 치료용 또는 예방용 조성물
JP7250674B2 (ja)	2016-08-08	2023-04-03	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	がんの治療及び診断方法
EP3500594A4 (en)	2016-08-22	2020-03-11	Cho Pharma Inc.	ANTIBODIES, BINDING FRAGMENTS AND METHOD FOR USE
AU2017321973B2 (en)	2016-09-02	2024-09-05	Dana-Farber Cancer Institute, Inc.	Composition and methods of treating B cell disorders
EP3510046A4 (en)	2016-09-07	2020-05-06	The Regents of the University of California	ANTIBODIES AGAINST OXIDATION-SPECIFIC EPITOPES
SG10201607778XA (en)	2016-09-16	2018-04-27	Chugai Pharmaceutical Co Ltd	Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
EP3515932B1 (en)	2016-09-19	2023-11-22	F. Hoffmann-La Roche AG	Complement factor based affinity chromatography
PL3528838T3 (pl)	2016-09-23	2023-12-18	F. Hoffmann-La Roche Ag	Zastosowania antagonistów IL-13 do leczenia atopowego zapalenia skóry
JOP20190055A1 (ar)	2016-09-26	2019-03-24	Merck Sharp & Dohme	أجسام مضادة ضد cd27
MX2019003703A (es)	2016-09-30	2020-08-13	Janssen Biotech Inc	Método seguro y eficaz para tratar la psoriasis con el anticuerpo específico anti-il23.
KR20190062505A (ko)	2016-10-03	2019-06-05	주노 쎄러퓨티크스 인코퍼레이티드	Hpv-특이적 결합 분자
EP3522933B1 (en)	2016-10-05	2021-12-15	F. Hoffmann-La Roche AG	Methods for preparing antibody drug conjugates
WO2018068028A1 (en)	2016-10-06	2018-04-12	Genentech, Inc.	Therapeutic and diagnostic methods for cancer
WO2018068201A1 (en)	2016-10-11	2018-04-19	Nanjing Legend Biotech Co., Ltd.	Single-domain antibodies and variants thereof against ctla-4
CN109862919A (zh)	2016-10-11	2019-06-07	免疫医疗有限公司	抗体-药物缀合物联合免疫介导的治疗剂
CN110267678A (zh)	2016-10-29	2019-09-20	霍夫曼-拉罗奇有限公司	抗mic抗体和使用方法
MX2019004834A (es)	2016-11-02	2019-06-20	Jounce Therapeutics Inc	Anticuerpos de pd-1 y usos de estos.
KR20190074300A (ko)	2016-11-15	2019-06-27	제넨테크, 인크.	항-cd20/항-cd3 이중특이적 항체에 의한 치료를 위한 투약
US11208474B2 (en)	2016-11-16	2021-12-28	Janssen Biotech, Inc.	Method of treating psoriasis with anti-IL23 specific antibody
JOP20190100A1 (ar)	2016-11-19	2019-05-01	Potenza Therapeutics Inc	بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
JP7313684B2 (ja)	2016-11-21	2023-07-25	キュレアブゲーエムベーハー	抗ｇｐ７３抗体及びイムノコンジュゲート
WO2018102746A1 (en)	2016-12-02	2018-06-07	Rigel Pharmaceuticals, Inc.	Antigen binding molecules to tigit
JP7193457B2 (ja)	2016-12-07	2022-12-20	ジェネンテック，インコーポレイテッド	抗ｔａｕ抗体及び使用方法
KR102603681B1 (ko)	2016-12-07	2023-11-17	아게누스 인코포레이티드	항체 및 이의 사용방법
JP2020511937A (ja)	2016-12-07	2020-04-23	ジェネンテック，インコーポレイテッド	抗ｔａｕ抗体及び使用方法
CA3045495A1 (en)	2016-12-12	2018-06-21	Genentech, Inc.	Methods of treating cancer using anti-pd-l1 antibodies and antiandrogens
KR102669762B1 (ko)	2016-12-19	2024-05-30	에프. 호프만-라 로슈 아게	표적화된 4-1bb(cd137) 작용물질과의 병용 요법
CA3039446A1 (en)	2016-12-20	2018-06-28	F. Hoffmann-La Roche Ag	Combination therapy of anti-cd20/anti-cd3 bispecific antibodies and 4-1bb (cd137) agonists
JOP20190134A1 (ar)	2016-12-23	2019-06-02	Potenza Therapeutics Inc	بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
JP7122311B2 (ja)	2017-01-03	2022-08-19	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	抗４－１ｂｂクローン２０ｈ４．９を含む二重特異性抗原結合分子
TW201825515A (zh)	2017-01-04	2018-07-16	美商伊繆諾金公司	Ｍｅｔ抗體以及其免疫結合物及用途
US11274157B2 (en)	2017-01-12	2022-03-15	Eureka Therapeutics, Inc.	Constructs targeting histone H3 peptide/MHC complexes and uses thereof
WO2018147960A1 (en)	2017-02-08	2018-08-16	Imaginab, Inc.	Extension sequences for diabodies
WO2018148660A1 (en)	2017-02-10	2018-08-16	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
SG11201907364WA (en)	2017-02-10	2019-09-27	Genentech Inc	Anti-tryptase antibodies, compositions thereof, and uses thereof
MX2019010295A (es)	2017-03-01	2019-11-21	Genentech Inc	Métodos de diagnóstico y terapéuticos para el cáncer.
CA3056248A1 (en)	2017-03-22	2018-09-27	Genentech, Inc.	Optimized antibody compositions for treatment of ocular disorders
JP2020515543A (ja)	2017-03-28	2020-05-28	ジェネンテック，インコーポレイテッド	神経変性疾患の治療方法
EP3601346A1 (en)	2017-03-29	2020-02-05	H. Hoffnabb-La Roche Ag	Bispecific antigen binding molecule for a costimulatory tnf receptor
WO2018178055A1 (en)	2017-03-29	2018-10-04	F. Hoffmann-La Roche Ag	Bispecific antigen binding molecule for a costimulatory tnf receptor
JOP20190203A1 (ar)	2017-03-30	2019-09-03	Potenza Therapeutics Inc	بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
SG11201909218RA (en)	2017-04-03	2019-11-28	Hoffmann La Roche	Antibodies binding to steap-1
MX2019011907A (es)	2017-04-04	2020-01-09	Hoffmann La Roche	Nuevas moleculas de union a antigeno biespecificas capaces de unirse especificamente a cd40 y a fap.
UA128451C2 (uk)	2017-04-05	2024-07-17	Ф. Хоффманн-Ля Рош Аг	Біспецифічне антитіло, яке специфічно зв'язується з pd1 і lag3
PL3606954T3 (pl)	2017-04-05	2022-10-17	F. Hoffmann-La Roche Ag	Przeciwciała anty-LAG3
CA3058478A1 (en)	2017-04-14	2018-10-18	Genentech, Inc.	Diagnostic and therapeutic methods for cancer
US20190078160A1 (en)	2017-04-21	2019-03-14	Genentech, Inc.	Use of klk5 antagonists for treatment of a disease
MY201065A (en)	2017-04-26	2024-02-01	Eureka Therapeutics Inc	Constructs specifically recognizing glypican 3 and uses thereof
TWI791519B (zh)	2017-04-27	2023-02-11	美商提薩羅有限公司	針對淋巴細胞活化基因-3（lag-3）之抗體藥劑及其用途
US11203638B2 (en)	2017-05-05	2021-12-21	Allakos Inc.	Methods and compositions for treating perennial allergic conjunctivitis and keratoconjunctivitis
US11091555B2 (en)	2017-05-16	2021-08-17	Five Prime Therapeutics, Inc.	Method of treating gastric cancer with anti-FGFR2-IIIb antibodies and modified FOLFOX6 chemotherapy
WO2019011918A1 (en)	2017-07-10	2019-01-17	International - Drug - Development - Biotech	TREATMENT OF LYMPHOCYTE B MALIGNANCIES USING AFUCOSYLATED PRO-APOPTOTIC ANTI-CD19 ANTIBODIES IN COMBINATION WITH ANTI-CD20 ANTIBODIES OR CHEMOTHERAPEUTIC AGENTS
KR20200093518A (ko)	2017-07-21	2020-08-05	제넨테크, 인크.	암에 대한 치료 및 진단 방법
SG11202000658PA (en)	2017-07-26	2020-02-27	Forty Seven Inc	Anti-sirp-alpha antibodies and related methods
EP3672990A1 (en)	2017-08-25	2020-07-01	Five Prime Therapeutics, Inc.	B7-h4 antibodies and methods of use thereof
WO2019059411A1 (en)	2017-09-20	2019-03-28	Chugai Seiyaku Kabushiki Kaisha	DOSAGE FOR POLYTHERAPY USING PD-1 AXIS BINDING ANTAGONISTS AND GPC3 TARGETING AGENT
TW201922780A (zh)	2017-09-25	2019-06-16	美商健生生物科技公司	以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
AU2018345539A1 (en)	2017-10-03	2020-04-16	Editas Medicine, Inc.	HPV-specific binding molecules
EP3694552A1 (en)	2017-10-10	2020-08-19	Tilos Therapeutics, Inc.	Anti-lap antibodies and uses thereof
AU2018347521A1 (en)	2017-10-12	2020-05-07	Immunowake Inc.	VEGFR-antibody light chain fusion protein
JP2021500902A (ja)	2017-11-01	2021-01-14	エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト	新規ｔｎｆファミリーリガンド三量体含有抗原結合分子
MX2020004243A (es)	2017-11-01	2020-09-25	Juno Therapeutics Inc	Receptores de anticuerpos y de antigenos quimericos especificos para el antigeno de maduracion de celulas b.
MX2020004573A (es)	2017-11-01	2020-09-25	Hoffmann La Roche	Terapia de combinacion con agonistas de ox40 dirigidos.
CN111182944B (zh)	2017-11-01	2022-11-22	豪夫迈·罗氏有限公司	双特异性2+1 Contorsbody
EP3707510B1 (en)	2017-11-06	2024-06-26	F. Hoffmann-La Roche AG	Diagnostic and therapeutic methods for cancer
CN111615520A (zh)	2017-12-01	2020-09-01	辉瑞大药厂	抗cxcr5抗体及其组合物和用途
EP3720877A1 (en)	2017-12-08	2020-10-14	Argenx BVBA	Use of fcrn antagonists for treatment of generalized myasthenia gravis
EP3724225A1 (en)	2017-12-15	2020-10-21	Juno Therapeutics, Inc.	Anti-cct5 binding molecules and methods of use thereof
EP3502140A1 (en)	2017-12-21	2019-06-26	F. Hoffmann-La Roche AG	Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
MX2020006119A (es)	2017-12-21	2020-08-24	Hoffmann La Roche	Anticuerpos de union a hla-a2/wt1.
EP3728321A1 (en)	2017-12-22	2020-10-28	F. Hoffmann-La Roche AG	Use of pilra binding agents for treatment of a disease
TWI833724B (zh)	2017-12-22	2024-03-01	美商永斯醫療股份有限公司	抗ｌｉｌｒｂ２抗體
WO2019129211A1 (en)	2017-12-28	2019-07-04	Nanjing Legend Biotech Co., Ltd.	Antibodies and variants thereof against pd-l1
CN117050184A (zh)	2017-12-28	2023-11-14	南京传奇生物科技有限公司	针对tigit的单域抗体和其变体
CN111511400A (zh)	2017-12-29	2020-08-07	豪夫迈·罗氏有限公司	抗vegf抗体及其使用方法
WO2019136029A1 (en)	2018-01-02	2019-07-11	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Neutralizing antibodies to ebola virus glycoprotein and their use
US11466077B2 (en)	2018-01-05	2022-10-11	Ac Immune Sa	Misfolded TDP-43 binding molecules
EP3508499A1 (en)	2018-01-08	2019-07-10	iOmx Therapeutics AG	Antibodies targeting, and other modulators of, an immunoglobulin gene associated with resistance against anti-tumour immune responses, and uses thereof
CN111699200B (zh)	2018-01-15	2023-05-26	南京传奇生物科技有限公司	针对pd-1的单域抗体和其变体
WO2019143636A1 (en)	2018-01-16	2019-07-25	Lakepharma, Inc.	Bispecific antibody that binds cd3 and another target
JP7345479B2 (ja)	2018-01-26	2023-09-15	ジェネンテック，インコーポレイテッド	組成物及び使用方法
CN111655717A (zh)	2018-01-26	2020-09-11	豪夫迈·罗氏有限公司	IL-22 Fc融合蛋白及使用方法
JP7438953B2 (ja)	2018-02-01	2024-02-27	イノベントバイオロジックス（スウツォウ）カンパニー，リミテッド	完全ヒト化抗ｂ細胞成熟抗原（ｂｃｍａ）の単鎖抗体およびその応用
JP7475275B2 (ja)	2018-02-08	2024-04-26	ジェネンテック，インコーポレイテッド	二重特異性抗原結合分子及びその使用方法
TWI829667B (zh)	2018-02-09	2024-01-21	瑞士商赫孚孟拉羅股份公司	結合gprc5d之抗體
CA3088557C (en)	2018-02-09	2024-02-27	Genentech, Inc.	Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases
CA3091646A1 (en)	2018-02-14	2019-08-22	Abba Therapeutics Ag	Anti-human pd-l2 antibodies
MA51903A (fr)	2018-02-21	2021-05-26	Five Prime Therapeutics Inc	Formulations d'anticorps b7-h4
TW201946647A (zh)	2018-02-21	2019-12-16	美商建南德克公司	利用il-22 fc融合蛋白進行治療之投藥
KR20200123169A (ko)	2018-02-21	2020-10-28	파이브 프라임 테라퓨틱스, 인크.	B7-h4 항체 투약 섭생법
AU2019226034A1 (en)	2018-02-21	2020-10-15	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Neutralizing antibodies to HIV-1 Env and their use
MX2020008882A (es)	2018-02-26	2021-01-08	Genentech Inc	Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1.
EA202091810A1 (ru)	2018-03-02	2021-01-29	Файв Прайм Терапьютикс, Инк.	Антитела к b7-h4 и способы их применения
IL310216A (en)	2018-03-05	2024-03-01	Janssen Biotech Inc	Methods for treating Crohn's disease with a specific anti-IL23 antibody
TWI841551B (zh)	2018-03-13	2024-05-11	瑞士商赫孚孟拉羅股份公司	使用靶向4-1bb (cd137)之促效劑的組合療法
KR20200132913A (ko)	2018-03-13	2020-11-25	에프. 호프만-라 로슈 아게	4-1bb 작용제와 항-cd20 항체의 치료 조합
US20200040103A1 (en)	2018-03-14	2020-02-06	Genentech, Inc.	Anti-klk5 antibodies and methods of use
MX2020009514A (es)	2018-03-14	2020-12-07	Beijing Xuanyi Pharmasciences Co Ltd	Anticuerpos anti-claudina 18.2 (cldn18.2).
TWI827585B (zh)	2018-03-15	2024-01-01	日商中外製藥股份有限公司	對茲卡病毒具有交叉反應性的抗登革病毒抗體及其使用方法
BR112020019083A2 (pt)	2018-03-21	2020-12-29	Five Prime Therapeutics, Inc.	Anticorpos, ácido nucleico, composições, célula e métodos para preparar um anticorpo, para tratar câncer, para tratar uma doença infecciosa, para tratar uma inflamação, para a identificação de um anticorpo, para melhorar a eficácia antitumoral de um anticorpo, para melhorar a farmacocinética de um anticorpo, para selecionar um anticorpo, para melhorar a eficácia de anticorpos, para isolar anticorpos, para detectar vista em uma amostra e para tratar câncer
JP2021519073A (ja)	2018-03-29	2021-08-10	ジェネンテック，インコーポレイテッド	哺乳動物細胞におけるラクトジェニック活性の制御
SG11202006674QA (en)	2018-03-30	2020-08-28	Nanjing Legend Biotech Co Ltd	Single-domain antibodies against lag-3 and uses thereof
TW202011029A (zh)	2018-04-04	2020-03-16	美商建南德克公司	偵測及定量fgf21之方法
AU2019249209A1 (en)	2018-04-05	2020-10-15	Juno Therapeutics, Inc.	T cell receptors and engineered cells expressing same
AR114284A1 (es)	2018-04-13	2020-08-12	Hoffmann La Roche	Moléculas de unión a antígeno dirigidas a her2 que comprenden 4-1bbl
US20190345245A1 (en)	2018-05-11	2019-11-14	Janssen Biotech, Inc.	Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
CN113840832A (zh)	2018-05-14	2021-12-24	狼人治疗公司	可活化白介素-2多肽及其使用方法
AU2019271147A1 (en)	2018-05-14	2020-12-17	Werewolf Therapeutics, Inc.	Activatable cytokine polypeptides and methods of use thereof
CA3098103A1 (en)	2018-05-23	2019-11-28	Adc Therapeutics Sa	Molecular adjuvant
WO2019228514A1 (en)	2018-06-01	2019-12-05	Tayu Huaxia Biotech Medical Group Co., Ltd.	Compositions and uses thereof for treating disease or condition
US20210221908A1 (en)	2018-06-03	2021-07-22	Lamkap Bio Beta Ltd.	Bispecific antibodies against ceacam5 and cd47
US20210238308A1 (en)	2018-06-04	2021-08-05	Chugai Seiyaku Kabushiki Kaisha	Antigen-binding molecule showing changed half-life in cytoplasm
SG11202012342WA (en)	2018-06-18	2021-01-28	Eureka Therapeutics Inc	Constructs targeting prostate-specific membrane antigen (psma) and uses thereof
CA3103017A1 (en)	2018-06-23	2019-12-26	Genentech, Inc.	Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
JP2021528988A (ja)	2018-07-04	2021-10-28	エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト	新規の二重特異性アゴニスト４−１ｂｂ抗原結合分子
EP3820904A2 (en)	2018-07-09	2021-05-19	Five Prime Therapeutics, Inc.	Antibodies binding to ilt4
WO2020014306A1 (en)	2018-07-10	2020-01-16	Immunogen, Inc.	Met antibodies and immunoconjugates and uses thereof
KR20210031722A (ko)	2018-07-11	2021-03-22	파이브 프라임 테라퓨틱스, 인크.	산성 pH에서 VISTA에 결합하는 항체
EP3824295A4 (en)	2018-07-18	2022-04-27	Janssen Biotech, Inc.	PREDICTORS OF PROLONGED RESPONSE AFTER TREATMENT WITH AN ANTI-IL23 SPECIFIC ANTIBODY
CN112839644A (zh)	2018-07-18	2021-05-25	豪夫迈·罗氏有限公司	用pd-1轴结合拮抗剂、抗代谢物和铂剂治疗肺癌的方法
WO2020018879A1 (en)	2018-07-20	2020-01-23	Surface Oncology, Inc.	Anti-cd112r compositions and methods
BR112021001693A2 (pt)	2018-08-03	2021-05-04	Chugai Seiyaku Kabushiki Kaisha	molécula de ligação ao antígeno contendo dois domínios de ligação ao antígeno q ligados entre si
MA50586A (fr)	2018-08-09	2020-09-16	Regeneron Pharma	Procédés d'évaluation de l'affinité de liaison d'une variante d'anticorps au récepteur fc néonatal
CA3108369A1 (en)	2018-08-10	2020-02-13	Tomoyuki Igawa	Anti-cd137 antigen-binding molecule and utilization thereof
AU2019324170A1 (en)	2018-08-23	2021-02-18	Seagen, Inc.	Anti-TIGIT antibodies
GB201814281D0 (en)	2018-09-03	2018-10-17	Femtogenix Ltd	Cytotoxic agents
WO2020052542A1 (en)	2018-09-10	2020-03-19	Nanjing Legend Biotech Co., Ltd.	Single-domain antibodies against cll1 and constructs thereof
WO2020061060A1 (en)	2018-09-19	2020-03-26	Genentech, Inc.	Therapeutic and diagnostic methods for bladder cancer
WO2020061349A1 (en)	2018-09-21	2020-03-26	Genentech, Inc.	Diagnostic methods for triple-negative breast cancer
EP3853249A4 (en)	2018-09-21	2022-06-22	The University of North Carolina at Chapel Hill	SYNTHETIC BINDERS TO LIMIT PERMEATION THROUGH MUCUS
HUE063462T2 (hu)	2018-09-24	2024-01-28	Janssen Biotech Inc	A colitis ulcerosa kezelésének biztonságos és hatékony eljárása anti-IL12/IL23 antitesttel
CN113286812A (zh)	2018-09-27	2021-08-20	西里欧发展公司	掩蔽型细胞因子多肽
JP7221379B2 (ja)	2018-10-01	2023-02-13	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	抗ｆａｐクローン２１２を含む二重特異性抗原結合分子
CN112654641A (zh)	2018-10-01	2021-04-13	豪夫迈·罗氏有限公司	具有与cd40的三价结合的双特异性抗原结合分子
EP3632929A1 (en)	2018-10-02	2020-04-08	Ospedale San Raffaele S.r.l.	Antibodies and uses thereof
CA3112215A1 (en)	2018-10-05	2020-04-09	Five Prime Therapeutics, Inc.	Anti-fgfr2 antibody formulations
US11130802B2 (en)	2018-10-10	2021-09-28	Tilos Therapeutics, Inc.	Anti-lap antibody variants
JP7448552B2 (ja)	2018-10-15	2024-03-12	ファイヴプライムセラピューティクスインク	がんの併用療法
WO2020081493A1 (en)	2018-10-16	2020-04-23	Molecular Templates, Inc.	Pd-l1 binding proteins
EP3867646A1 (en)	2018-10-18	2021-08-25	F. Hoffmann-La Roche AG	Diagnostic and therapeutic methods for sarcomatoid kidney cancer
US20210395390A1 (en)	2018-10-31	2021-12-23	Bayer Aktiengesellschaft	Reversal agents for neutralizing the therapeutic activity of anti-fxia antibodies
EP3880714A4 (en)	2018-11-16	2022-07-20	Memorial Sloan Kettering Cancer Center	ANTIBODIES TO MUCIN-16 AND METHODS OF USE THEREOF
EP3883607A4 (en)	2018-11-20	2022-08-17	Janssen Biotech, Inc.	SAFE AND EFFECTIVE PROCESS FOR TREATING PSORIASIS WITH A SPECIFIC ANTI-IL-23 ANTIBODY
EP3891185A2 (en)	2018-12-05	2021-10-13	F. Hoffmann-La Roche AG	Diagnostic methods and compositions for cancer immunotherapy
EP3892299A4 (en)	2018-12-07	2022-11-30	ONO Pharmaceutical Co., Ltd.	IMMUNOSUPPRESSANT
JP2022513198A (ja)	2018-12-10	2022-02-07	ジェネンテック，インコーポレイテッド	Ｆｃ含有タンパク質への部位特異的コンジュゲーションのための光架橋性ペプチド
JP2022514561A (ja)	2018-12-18	2022-02-14	ヤンセンバイオテツク，インコーポレーテツド	抗ｉｌ１２／ｉｌ２３抗体でループスを治療する安全かつ有効な方法
EP3898667A2 (en)	2018-12-20	2021-10-27	F. Hoffmann-La Roche AG	Modified antibody fcs and methods of use
US20220089694A1 (en)	2018-12-20	2022-03-24	The U.S.A., As Represented By The Secretary, Department Of Health And Human Services	Ebola virus glycoprotein-specific monoclonal antibodies and uses thereof
SG11202106198YA (en)	2018-12-21	2021-07-29	Hoffmann La Roche	Antibody that binds to vegf and il-1beta and methods of use
MY194642A (en)	2018-12-21	2022-12-09	Hoffmann La Roche	Antibodies binding to cd3
CR20210326A (es)	2018-12-21	2021-09-10	Hoffmann La Roche	Moléculas agonistas de unión al antígeno cd28 que actúan sobre el tumor
US20200223925A1 (en)	2018-12-21	2020-07-16	Hoffmann-La Roche Inc.	Tumor-targeted superagonistic cd28 antigen binding molecules
SG11202106498XA (en)	2018-12-26	2021-07-29	Xilio Development Inc	Anti-ctla4 antibodies and methods of use thereof
CN113272327A (zh)	2018-12-30	2021-08-17	豪夫迈·罗氏有限公司	抗兔cd19抗体及其使用方法
KR20210116525A (ko)	2019-01-14	2021-09-27	제넨테크, 인크.	Pd-1 축 결합 길항제 및 rna 백신으로 암을 치료하는 방법
WO2020148379A1 (en)	2019-01-17	2020-07-23	Bayer Aktiengesellschaft	Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc)
JPWO2020153467A1 (ja)	2019-01-24	2021-12-02	中外製薬株式会社	新規がん抗原及びそれらの抗原に対する抗体
GB201901197D0 (en)	2019-01-29	2019-03-20	Femtogenix Ltd	G-A Crosslinking cytotoxic agents
EA202192103A1 (ru)	2019-01-29	2021-12-15	Джуно Терапьютикс, Инк.	Антитела и химерные антигенные рецепторы, специфичные к орфанному рецептору типа рецеторной тирозинкиназы 1 (ror1)
WO2020176748A1 (en)	2019-02-27	2020-09-03	Genentech, Inc.	Dosing for treatment with anti-tigit and anti-cd20 or anti-cd38 antibodies
TW202101000A (zh)	2019-03-08	2021-01-01	美商建南德克公司	用於偵測且量化膜相關蛋白之方法
WO2020183418A1 (en)	2019-03-14	2020-09-17	Janssen Biotech, Inc.	Manufacturing methods for producing anti-il12/il23 antibody compositions
UA128654C2 (uk)	2019-03-14	2024-09-18	Дженентек, Інк.	Лікування раку біспецифічними антитілами до her2xcd3 у комбінації з моноклональним антитілом до her2
BR112021018441A2 (pt)	2019-03-18	2023-02-28	Janssen Biotech Inc	Método para tratamento de psoríase em indivíduos pediátricos com anticorpo anti-il12/il23
GB2589049C (en)	2019-04-11	2024-02-21	argenx BV	Anti-IgE antibodies
CN113677403A (zh)	2019-04-12	2021-11-19	豪夫迈·罗氏有限公司	包含脂质运载蛋白突变蛋白的双特异性抗原结合分子
EP3956364A1 (en)	2019-04-19	2022-02-23	F. Hoffmann-La Roche AG	Anti-mertk antibodies and their methods of use
US20220143094A1 (en)	2019-04-19	2022-05-12	Chugai Seiyaku Kabushiki Kaisha	Chimeric receptor that recognizes engineered site in antibody
AU2020270376A1 (en)	2019-05-03	2021-10-07	Genentech, Inc.	Methods of treating cancer with an anti-PD-L1 antibody
WO2020227228A2 (en)	2019-05-03	2020-11-12	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
KR20220023988A (ko)	2019-05-14	2022-03-03	웨어울프 세라퓨틱스, 인크.	분리 모이어티 및 이의 사용 방법
CN114206340A (zh)	2019-05-14	2022-03-18	豪夫迈·罗氏有限公司	使用抗cd79b免疫缀合物治疗滤泡性淋巴瘤的方法
US20230085439A1 (en)	2019-05-21	2023-03-16	University Of Georgia Research Foundation, Inc.	Antibodies that bind human metapneumovirus fusion protein and their use
MX2021014302A (es)	2019-05-23	2022-01-04	Janssen Biotech Inc	Metodo para tratar la enfermedad inflamatoria del intestino con una terapia de combinacion de anticuerpos contra il-23 y tnf alfa.
JP2022533432A (ja)	2019-05-23	2022-07-22	エイシーイミューンソシエテアノニム	抗ｔｄｐ－４３結合分子およびその使用
JP7565951B2 (ja)	2019-06-07	2024-10-11	アルジェニクスビーブイ	皮下投与に好適なＦｃＲｎインヒビターの医薬製剤
KR20220025848A (ko)	2019-06-26	2022-03-03	에프. 호프만-라 로슈 아게	Cea 및 4-1bbl에 결합하는 항체의 융합
WO2020260326A1 (en)	2019-06-27	2020-12-30	F. Hoffmann-La Roche Ag	Novel icos antibodies and tumor-targeted antigen binding molecules comprising them
WO2021003297A1 (en)	2019-07-02	2021-01-07	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Monoclonal antibodies that bind egfrviii and their use
CN114401992A (zh)	2019-07-05	2022-04-26	艾欧麦克斯治疗股份公司	结合igsf11（vsig3）的igc2的抗体及其用途
CN114341187A (zh)	2019-07-12	2022-04-12	中外制药株式会社	抗突变型fgfr3抗体及其用途
AR119382A1 (es)	2019-07-12	2021-12-15	Hoffmann La Roche	Anticuerpos de pre-direccionamiento y métodos de uso
AR119393A1 (es)	2019-07-15	2021-12-15	Hoffmann La Roche	Anticuerpos que se unen a nkg2d
US20220289828A1 (en)	2019-07-26	2022-09-15	Vanderbilt University	Human monoclonal antibodies to enterovirus d68
EP4004045A1 (en)	2019-07-31	2022-06-01	F. Hoffmann-La Roche AG	Antibodies binding to gprc5d
PE20220394A1 (es)	2019-07-31	2022-03-18	Hoffmann La Roche	Anticuerpos que se fijan a gprc5d
AU2020325770B2 (en)	2019-08-06	2022-08-25	Aprinoia Therapeutics Limited	Antibodies that bind to pathological tau species and uses thereof
JP2022547577A (ja)	2019-09-12	2022-11-14	ジェネンテック，インコーポレイテッド	ループス腎炎を治療する組成物及び方法
PE20221906A1 (es)	2019-09-18	2022-12-23	Genentech Inc	Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecificos anti-klk5/klk7 y metodos de uso
PE20220566A1 (es)	2019-09-19	2022-04-13	Bristol Myers Squibb Co	ANTICUERPOS DE UNION A VISTA A pH ACIDO
AU2020348393A1 (en)	2019-09-20	2022-02-24	Genentech, Inc.	Dosing for anti-tryptase antibodies
EP4424321A2 (en)	2019-09-27	2024-09-04	F. Hoffmann-La Roche AG	Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
CR20220166A (es)	2019-10-18	2022-06-15	Genentech Inc	Métodos para usar inmunoconjugados anti-cd79b para tratar linfoma difuso de linfocitos b grandes
CA3155922A1 (en)	2019-11-06	2021-05-14	Huang Huang	Diagnostic and therapeutic methods for treatment of hematologic cancers
CA3155981A1 (en)	2019-11-14	2021-05-20	William Winston	Activatable cytokine polypeptides and methods of use thereof
CN114651006A (zh)	2019-11-15	2022-06-21	恩瑟拉有限责任公司	Tmem219抗体及其治疗性用途
EP3822288A1 (en)	2019-11-18	2021-05-19	Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts	Antibodies targeting, and other modulators of, the cd276 antigen, and uses thereof
US20230039165A1 (en)	2019-11-21	2023-02-09	Enthera S.R.L.	Igfbp3 antibodies and therapeutic uses thereof
EP3831849A1 (en)	2019-12-02	2021-06-09	LamKap Bio beta AG	Bispecific antibodies against ceacam5 and cd47
AU2020395319A1 (en)	2019-12-06	2022-07-14	Juno Therapeutics, Inc.	Anti-idiotypic antibodies to BCMA-targeted binding domains and related compositions and methods
CN115335399A (zh)	2019-12-06	2022-11-11	朱诺治疗学股份有限公司	针对gprc5d靶结合结构域的抗独特型抗体以及相关组合物和方法
BR112022011357A2 (pt)	2019-12-13	2022-08-23	Genentech Inc	Anticorpos isolado, um ou mais ácidos nucleicos isolados, um ou mais vetores, uma ou mais células hospedeiras, composição, kit, uso do anticorpo, métodos para produzir o anticorpo e método para tratar ou retardar a progressão de um câncer ly6g6d positivo
WO2021122875A1 (en)	2019-12-18	2021-06-24	F. Hoffmann-La Roche Ag	Antibodies binding to hla-a2/mage-a4
CN113045655A (zh)	2019-12-27	2021-06-29	高诚生物医药(香港)有限公司	抗ox40抗体及其用途
US20230058982A1 (en)	2019-12-27	2023-02-23	Chugai Seiyaku Kabushiki Kaisha	Anti-ctla-4 antibody and use thereof
EP4087875B1 (en)	2020-01-08	2024-08-28	Argenx BV	Antagonists of human neonatal fc receptor (fcrn) for treating pemphigus disorders
WO2021140130A1 (en)	2020-01-09	2021-07-15	F. Hoffmann-La Roche Ag	New 4-1bbl trimer-containing antigen binding molecules
CN110818795B (zh)	2020-01-10	2020-04-24	上海复宏汉霖生物技术股份有限公司	抗tigit抗体和使用方法
WO2022050954A1 (en)	2020-09-04	2022-03-10	Genentech, Inc.	Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2021194481A1 (en)	2020-03-24	2021-09-30	Genentech, Inc.	Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2021155295A1 (en)	2020-01-31	2021-08-05	The Cleveland Clinic Foundation	Anti-müllerian hormone receptor 2 antibodies and methods of use
MX2022009391A (es)	2020-01-31	2022-09-26	Genentech Inc	Metodos para inducir linfocitos t especificos para neoepitopo con un antagonista de union al eje de pd-1 y una vacuna de arn.
AU2021220847A1 (en)	2020-02-11	2022-09-01	Vanderbilt University	Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV- 2)
TW202144395A (zh)	2020-02-12	2021-12-01	日商中外製藥股份有限公司	用於癌症之治療的抗cd137抗原結合分子
AU2021219668A1 (en)	2020-02-14	2022-08-25	Gilead Sciences, Inc.	Antibodies and fusion proteins that bind to CCR8 and uses thereof
WO2021168292A1 (en)	2020-02-20	2021-08-26	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Epstein-barr virus monoclonal antibodies and uses thereof
EP3868396A1 (en)	2020-02-20	2021-08-25	Enthera S.R.L.	Inhibitors and uses thereof
BR112022016491A2 (pt)	2020-02-28	2022-10-11	Shanghai Henlius Biotech Inc	Construto anti-cd137 e usos do mesmo
CN115151573A (zh)	2020-02-28	2022-10-04	上海复宏汉霖生物技术股份有限公司	抗cd137构建体、多特异性抗体及其用途
CN115315446A (zh)	2020-03-06	2022-11-08	Go医疗股份有限公司	抗糖-cd44抗体及其用途
WO2021183849A1 (en)	2020-03-13	2021-09-16	Genentech, Inc.	Anti-interleukin-33 antibodies and uses thereof
CR20220524A (es)	2020-03-19	2022-12-02	Genentech Inc	Anticuerpos anti-tgf-beta con selectividad de isoforma y métodos de uso
US20230174656A1 (en)	2020-03-23	2023-06-08	Genentech, Inc.	Tocilizumab and remdesivir combination therapy for covid-19 pneumonia
US20240025991A1 (en)	2020-03-23	2024-01-25	Genentech, Inc.	Method for treating pneumonia, including covid-19 pneumonia, with an il6 antagonist
CN115867577A (zh)	2020-03-23	2023-03-28	基因泰克公司	用于预测covid-19肺炎中对il-6拮抗剂反应的生物标志物
US11999787B2 (en)	2020-03-24	2024-06-04	Genentech, Inc.	Tie2-binding agents and methods of use
PL4045533T3 (pl)	2020-03-26	2024-04-15	Vanderbilt University	Ludzkie przeciwciała monoklonalne przeciwko ciężkiemu ostremu zespołowi oddechowemu wywołanemu koronawirusem 2 (sars-cov-2)
WO2021195385A1 (en)	2020-03-26	2021-09-30	Vanderbilt University	HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-GoV-2)
KR20220159426A (ko)	2020-03-26	2022-12-02	제넨테크, 인크.	감소된 숙주 세포 단백질을 보유하는 변형된 포유동물 세포
AR121706A1 (es)	2020-04-01	2022-06-29	Hoffmann La Roche	Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
CN115698717A (zh)	2020-04-03	2023-02-03	基因泰克公司	癌症的治疗和诊断方法
EP4132971A1 (en)	2020-04-09	2023-02-15	Merck Sharp & Dohme LLC	Affinity matured anti-lap antibodies and uses thereof
WO2021207662A1 (en)	2020-04-10	2021-10-14	Genentech, Inc.	Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
BR112022021441A2 (pt)	2020-04-24	2022-12-13	Genentech Inc	Métodos para tratar linfoma folicular e linfoma difuso de grandes células b e kits
JP2023523145A (ja)	2020-04-27	2023-06-02	ザリージェンツオブザユニバーシティオブカリフォルニア	リポ蛋白（ａ）に対するイソ型非依存性抗体
EP4143345A1 (en)	2020-04-28	2023-03-08	Genentech, Inc.	Methods and compositions for non-small cell lung cancer immunotherapy
AU2021267995A1 (en)	2020-05-03	2022-12-08	Levena (Suzhou) Biopharma Co., Ltd.	Antibody-drug conjugates (ADCs) comprising an anti-Trop-2 antibody, compositions comprising such ADCs, as well as methods of making and using the same
IL297977A (en)	2020-05-17	2023-01-01	Astrazeneca Uk Ltd	sars-cov-2 antibodies and methods for selecting and using them
WO2021238886A1 (en)	2020-05-27	2021-12-02	Staidson (Beijing) Biopharmaceuticals Co., Ltd.	Antibodies specifically recognizing nerve growth factor and uses thereof
CN116529260A (zh)	2020-06-02	2023-08-01	当康生物技术有限责任公司	抗cd93构建体及其用途
BR112022024629A2 (pt)	2020-06-02	2023-02-23	Dynamicure Biotechnology Llc	Construtos anti-cd93 e seus usos
WO2021249990A2 (en)	2020-06-08	2021-12-16	Hoffmann-La Roche Inc.	Anti-hbv antibodies and methods of use
JP2023529206A (ja)	2020-06-12	2023-07-07	ジェネンテック，インコーポレイテッド	がん免疫療法のための方法及び組成物
KR20230025691A (ko)	2020-06-16	2023-02-22	제넨테크, 인크.	삼중 음성 유방암을 치료하기 위한 방법과 조성물
EP4168118A1 (en)	2020-06-18	2023-04-26	Genentech, Inc.	Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
CR20220637A (es)	2020-06-19	2023-01-31	Hoffmann La Roche	Anticuerpos que se unen a cd3 y cd19
WO2021255142A1 (en)	2020-06-19	2021-12-23	F. Hoffmann-La Roche Ag	Antibodies binding to cd3
WO2021255146A1 (en)	2020-06-19	2021-12-23	F. Hoffmann-La Roche Ag	Antibodies binding to cd3 and cea
CN115916826A (zh)	2020-06-19	2023-04-04	豪夫迈·罗氏有限公司	与CD3和FolR1结合的抗体
US12049515B2 (en)	2020-06-23	2024-07-30	Hoffmann-La Roche Inc.	Agonistic CD28 antigen binding molecules targeting Her2
CN115943158A (zh)	2020-06-24	2023-04-07	基因泰克公司	抗细胞凋亡的细胞系
JP2023531067A (ja)	2020-06-25	2023-07-20	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	抗ｃｄ３／抗ｃｄ２８二重特異性抗原結合分子
EP4175668A1 (en)	2020-07-06	2023-05-10	iOmx Therapeutics AG	Antibodies binding igv of igsf11 (vsig3) and uses thereof
CR20230076A (es)	2020-07-10	2023-03-13	Hoffmann La Roche	Anticuerpos que se unen a células cancerosas y dirigen radionucleótidos a dichas células
CR20230087A (es)	2020-07-17	2023-03-20	Genentech Inc	Anticuerpos anti-notch2 y métodos de uso
GB2597532A (en)	2020-07-28	2022-02-02	Femtogenix Ltd	Cytotoxic compounds
WO2022026763A1 (en)	2020-07-29	2022-02-03	Dynamicure Biotechnology Llc	Anti-cd93 constructs and uses thereof
JP2023536602A (ja)	2020-08-03	2023-08-28	ジェネンテック，インコーポレイテッド	リンパ腫のための診断及び治療方法
EP4192868A1 (en)	2020-08-05	2023-06-14	Juno Therapeutics, Inc.	Anti-idiotypic antibodies to ror1-targeted binding domains and related compositions and methods
CR20230119A (es)	2020-08-07	2023-05-16	Genentech Inc	Proteínas de fusión del ligando para flt3 y métodos de uso
AU2021325339A1 (en)	2020-08-10	2023-04-06	Astrazeneca Uk Limited	SARS-CoV-2 antibodies for treatment and prevention of COVID-19
CN116615452A (zh)	2020-08-14	2023-08-18	Ac免疫有限公司	人源化抗tdp-43结合分子及其用途
WO2022043517A2 (en)	2020-08-27	2022-03-03	Cureab Gmbh	Anti-golph2 antibodies for macrophage and dendritic cell differentiation
CN116648507A (zh)	2020-08-28	2023-08-25	基因泰克公司	宿主细胞蛋白的CRISPR/Cas9多重敲除
EP4208201A1 (en)	2020-09-04	2023-07-12	F. Hoffmann-La Roche AG	Antibody that binds to vegf-a and ang2 and methods of use
BR112023002800A2 (pt)	2020-09-15	2023-03-21	Bayer Ag	Anticorpos anti-a2ap e usos dos mesmos
WO2022060412A1 (en)	2020-09-17	2022-03-24	Genentech, Inc.	Results of empacta: a randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of tocilizumab in hospitalized patients with covid-19 pneumonia
KR20230082632A (ko)	2020-10-05	2023-06-08	제넨테크, 인크.	항-fcrh5/항-cd3 이중특이성 항체를 사용한 치료를 위한 투약
US20230372528A1 (en)	2020-10-16	2023-11-23	University Of Georgia Research Foundation, Inc.	Glycoconjugates
MX2023004342A (es)	2020-10-20	2023-05-04	Hoffmann La Roche	Politerapia de antagonistas de union al eje de pd-1 e inhibidores de lrrk2.
AU2021366287A1 (en)	2020-10-20	2023-04-13	Kantonsspital St. Gallen	Antibodies or antigen-binding fragments specifically binding to Gremlin-1 and uses thereof
WO2022086957A1 (en)	2020-10-20	2022-04-28	Genentech, Inc.	Peg-conjugated anti-mertk antibodies and methods of use
WO2022093981A1 (en)	2020-10-28	2022-05-05	Genentech, Inc.	Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
AU2021374803A1 (en)	2020-11-03	2023-06-22	Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts	Target-cell restricted, costimulatory, bispecific and bivalent anti-cd28 antibodies
US20220162329A1 (en)	2020-11-04	2022-05-26	Genentech, Inc.	Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
MX2023005131A (es)	2020-11-04	2023-05-25	Genentech Inc	Dosis para el tratamiento con anticuerpos biespecificos anti-cd20/anti-cd3 y conjugados anticuerpo farmaco anti-cd79b.
CA3196076A1 (en)	2020-11-04	2022-05-12	Chi-Chung Li	Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies
WO2022101458A1 (en)	2020-11-16	2022-05-19	F. Hoffmann-La Roche Ag	Combination therapy with fap-targeted cd40 agonists
AU2021391493A1 (en)	2020-12-02	2023-06-08	Glaxosmithkline Intellectual Property Development Limited	Il-7 binding proteins and their use in medical therapy
TW202237638A (zh)	2020-12-09	2022-10-01	日商武田藥品工業股份有限公司	烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
TW202237639A (zh)	2020-12-09	2022-10-01	日商武田藥品工業股份有限公司	鳥苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
WO2022132904A1 (en)	2020-12-17	2022-06-23	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Human monoclonal antibodies targeting sars-cov-2
KR20230117406A (ko)	2021-01-06	2023-08-08	에프. 호프만-라 로슈 아게	Pd1-lag3 이중특이성 항체와 cd20 t 세포 이중특이성항체를 이용한 조합 요법
KR20230131204A (ko)	2021-01-12	2023-09-12	에프. 호프만-라 로슈 아게	암 세포에 결합하여 방사성핵종을 상기 세포에 표적화하는분할 항체
MX2023008083A (es)	2021-01-13	2023-07-13	Hoffmann La Roche	Tratamiento conjunto.
WO2022162587A1 (en)	2021-01-27	2022-08-04	Centre Hospitalier Universitaire Vaudois (C.H.U.V.)	Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
WO2022162203A1 (en)	2021-01-28	2022-08-04	Vaccinvent Gmbh	Method and means for modulating b-cell mediated immune responses
CN117120084A (zh)	2021-01-28	2023-11-24	维肯芬特有限责任公司	用于调节b细胞介导的免疫应答的方法和手段
WO2022162201A1 (en)	2021-01-28	2022-08-04	Vaccinvent Gmbh	Method and means for modulating b-cell mediated immune responses
EP4288458A1 (en)	2021-02-03	2023-12-13	Genentech, Inc.	Multispecific binding protein degrader platform and methods of use
CN117642178A (zh)	2021-02-09	2024-03-01	美国政府(由卫生和人类服务部的部长所代表)	靶向冠状病毒刺突蛋白的抗体
US20240117019A1 (en)	2021-02-09	2024-04-11	University Of Georgia Research Foundation, Inc.	Human monoclonal antibodies against pneumococcal antigens
US20240226295A9 (en)	2021-02-15	2024-07-11	Takeda Pharmaceutical Company Limited	Cell therapy compositions and methods for modulating tgf-b signaling
GB202102396D0 (en)	2021-02-19	2021-04-07	Adc Therapeutics Sa	Molecular adjuvant
IL305131A (en)	2021-02-26	2023-10-01	Bayer Ag	IL-11 or IL-11Ra inhibitors for use in the treatment of abnormal uterine bleeding
WO2022187272A1 (en)	2021-03-01	2022-09-09	Xilio Development, Inc.	Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer
WO2022187270A1 (en)	2021-03-01	2022-09-09	Xilio Development, Inc.	Combination of ctla4 and pd1/pdl1 antibodies for treating cancer
WO2022184082A1 (en)	2021-03-03	2022-09-09	Sorrento Therapeutics, Inc.	Antibody-drug conjugates comprising an anti-bcma antibody
WO2022187591A1 (en)	2021-03-05	2022-09-09	Go Therapeutics, Inc.	Anti-glyco-cd44 antibodies and their uses
JP2024509191A (ja)	2021-03-05	2024-02-29	ダイナミキュアバイオテクノロジーエルエルシー	抗ｖｉｓｔａ構築物およびその使用
EP4304732A1 (en)	2021-03-12	2024-01-17	Genentech, Inc.	Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
IL305802A (en)	2021-03-12	2023-11-01	Janssen Biotech Inc	A safe and effective method for the treatment of rheumatoid arthritis with a specific anti-IL23 antibody
AU2022232007A1 (en)	2021-03-12	2023-10-26	Janssen Biotech, Inc.	Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody
IL305283A (en)	2021-03-15	2023-10-01	Genentech Inc	Compositions and methods for the treatment of lupus nephritis
WO2022197877A1 (en)	2021-03-19	2022-09-22	Genentech, Inc.	Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
TW202300648A (zh)	2021-03-25	2023-01-01	美商當康生物科技有限公司	抗-igfbp7構築體及其用途
CN117396504A (zh)	2021-03-30	2024-01-12	拜耳公司	抗Sema3A抗体及其用途
AR125344A1 (es)	2021-04-15	2023-07-05	Chugai Pharmaceutical Co Ltd	Anticuerpo anti-c1s
JP2024514222A (ja)	2021-04-19	2024-03-28	ジェネンテック，インコーポレイテッド	改変された哺乳動物細胞
EP4326271A1 (en)	2021-04-23	2024-02-28	F. Hoffmann-La Roche AG	Prevention or mitigation of nk cell engaging agent-related adverse effects
WO2022228705A1 (en)	2021-04-30	2022-11-03	F. Hoffmann-La Roche Ag	Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
CN118593725A (zh)	2021-05-12	2024-09-06	基因泰克公司	使用抗cd79b免疫缀合物治疗弥漫性大b细胞淋巴瘤的方法
AU2022273303A1 (en)	2021-05-14	2023-11-02	Genentech, Inc.	Agonists of trem2
WO2022243261A1 (en)	2021-05-19	2022-11-24	F. Hoffmann-La Roche Ag	Agonistic cd40 antigen binding molecules targeting cea
EP4341385A1 (en)	2021-05-21	2024-03-27	Genentech, Inc.	Modified cells for the production of a recombinant product of interest
CA3220227A1 (en)	2021-05-28	2022-12-01	Matthew Bruce	Combination therapies for treating cancer
AR126009A1 (es)	2021-06-02	2023-08-30	Hoffmann La Roche	Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
WO2022255440A1 (en)	2021-06-04	2022-12-08	Chugai Seiyaku Kabushiki Kaisha	Anti-ddr2 antibodies and uses thereof
BR112023025738A2 (pt)	2021-06-09	2024-02-27	Hoffmann La Roche	Combinação de um inibidor de braf e um antagonista de ligação ao eixo pd-1, uso de uma combinação de um inibidor de braf e um antagonista de ligação ao eixo pd-1, método para o tratamento ou profilaxia de câncer, composição farmacêutica e invenção
BR112023025863A2 (pt)	2021-06-11	2024-03-05	Genentech Inc	Métodos para tratar doença pulmonar obstrutiva crônica (dpoc), para reduzir a frequência de exacerbações moderadas a graves em um paciente com dpoc, para tratar ou prevenir dpoc, para manter e/ou melhorar a função pulmonar, para melhorar a contagem de linha de base de eosinófilos no sangue, kit, antagonistas de st2 e anticorpo anti-st2
WO2022266660A1 (en)	2021-06-17	2022-12-22	Amberstone Biosciences, Inc.	Anti-cd3 constructs and uses thereof
WO2022263638A1 (en)	2021-06-17	2022-12-22	Centre Hospitalier Universitaire Vaudois (C.H.U.V.)	Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
JP7477127B2 (ja)	2021-06-25	2024-05-01	中外製薬株式会社	抗ｃｔｌａ－４抗体の使用
MX2023013897A (es)	2021-06-25	2023-12-11	Chugai Pharmaceutical Co Ltd	Anticuerpo anti-antigeno 4 del linfocito t citotoxico (anti-ctla-4).
TW202317633A (zh)	2021-07-08	2023-05-01	美商舒泰神（加州）生物科技有限公司	特異性識別ｔｎｆｒ２的抗體及其用途
EP4367138A1 (en)	2021-07-09	2024-05-15	Janssen Biotech, Inc.	Manufacturing methods for producing anti-il12/il23 antibody compositions
TW202306985A (zh)	2021-07-12	2023-02-16	美商建南德克公司	降低抗體－脂酶結合之結構
MX2024000611A (es)	2021-07-14	2024-02-02	Genentech Inc	Anticuerpos anti-receptor de quimiocinas de motivo c-c 8 (ccr8) y metodos de uso.
US20240343817A1 (en)	2021-07-14	2024-10-17	Staidson (Beijing) Biopharmaceuticals Co., Ltd.	Antibody that specifically recognizes cd40 and application thereof
JP2024528631A (ja)	2021-07-22	2024-07-30	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	ヘテロ二量体Ｆｃドメイン抗体
WO2023004386A1 (en)	2021-07-22	2023-01-26	Genentech, Inc.	Brain targeting compositions and methods of use thereof
CN117794953A (zh)	2021-08-03	2024-03-29	豪夫迈·罗氏有限公司	双特异性抗体及使用方法
EP4380604A1 (en)	2021-08-05	2024-06-12	Go Therapeutics, Inc.	Anti-glyco-muc4 antibodies and their uses
US20240336697A1 (en)	2021-08-07	2024-10-10	Genentech, Inc.	Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
EP4384224A1 (en)	2021-08-13	2024-06-19	GlaxoSmithKline Intellectual Property Development Limited	Cytotoxicity targeting chimeras
WO2023019239A1 (en)	2021-08-13	2023-02-16	Genentech, Inc.	Dosing for anti-tryptase antibodies
JP2024529127A (ja)	2021-08-13	2024-08-01	グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド	Ｃｃｒ２発現細胞のための細胞傷害性標的キメラ
JP2024534067A (ja)	2021-08-19	2024-09-18	エフ．ホフマン－ラロシュアーゲー	多価抗バリアントｆｃ領域抗体および使用方法
JP2024534265A (ja)	2021-08-23	2024-09-18	イミュニタスセラピューティクス，インコーポレーテッド	抗ｃｄ１６１抗体及びその使用
AU2022332303A1 (en)	2021-08-27	2024-02-01	Genentech, Inc.	Methods of treating tau pathologies
TW202325727A (zh)	2021-08-30	2023-07-01	美商建南德克公司	抗聚泛素多特異性抗體
CN118355031A (zh)	2021-09-03	2024-07-16	Go医疗股份有限公司	抗糖-lamp1抗体及其用途
JP2024536722A (ja)	2021-09-03	2024-10-08	ジーオーセラピューティクス，インコーポレイテッド	抗グリコｃｍｅｔ抗体およびその使用
AU2022345251A1 (en)	2021-09-17	2024-03-28	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Synthetic humanized llama nanobody library and use thereof to identify sars-cov-2 neutralizing antibodies
TW202321308A (zh)	2021-09-30	2023-06-01	美商建南德克公司	使用抗ｔｉｇｉｔ抗體、抗ｃｄ３８抗體及ｐｄ—１軸結合拮抗劑治療血液癌症的方法
EP4412713A1 (en)	2021-10-05	2024-08-14	GlaxoSmithKline Intellectual Property Development Ltd	Combination therapies for treating cancer
IL311956A (en)	2021-10-08	2024-06-01	Chugai Pharmaceutical Co Ltd	Method for preparing a prefilled syringe formulation
WO2023073615A1 (en)	2021-10-29	2023-05-04	Janssen Biotech, Inc.	Methods of treating crohn's disease with anti-il23 specific antibody
WO2023078279A1 (zh) *	2021-11-04	2023-05-11	澄交生物科技股份有限公司	免疫原性组合物及其用途
KR20240099315A (ko)	2021-11-05	2024-06-28	아메리칸 다이어그노스틱스 앤드 테라피, 엘엘씨 (에이디엑스알엑스)	암배아성 항원에 대한 단클론성 항체 및 이의 용도
TW202342095A (zh)	2021-11-05	2023-11-01	英商阿斯特捷利康英國股份有限公司	用於治療和預防ｃｏｖｉｄ—１９之組成物
WO2023086807A1 (en)	2021-11-10	2023-05-19	Genentech, Inc.	Anti-interleukin-33 antibodies and uses thereof
MX2024005860A (es)	2021-11-15	2024-08-06	Janssen Biotech Inc	Métodos para tratar la enfermedad de crohn con el anticuerpo específico anti-il23.
AU2022389969A1 (en)	2021-11-16	2024-05-02	Genentech, Inc.	Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab
AR127692A1 (es)	2021-11-16	2024-02-21	Ac Immune Sa	Anticuerpos anti-asc para uso en tratamientos antiinflamatorios
US20230159633A1 (en)	2021-11-23	2023-05-25	Janssen Biotech, Inc.	Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
EP4437006A1 (en)	2021-11-26	2024-10-02	F. Hoffmann-La Roche AG	Combination therapy of anti-tyrp1/anti-cd3 bispecific antibodies and tyrp1-specific antibodies
WO2023103788A1 (zh)	2021-12-06	2023-06-15	北京三诺佳邑生物技术有限责任公司	特异性结合肺炎克雷伯菌o2抗原和o1抗原的双特异性抗体以及组合物
AR127887A1 (es)	2021-12-10	2024-03-06	Hoffmann La Roche	Anticuerpos que se unen a cd3 y plap
EP4448579A1 (en)	2021-12-17	2024-10-23	Shanghai Henlius Biotech, Inc.	Anti-ox40 antibodies and methods of use
WO2023109900A1 (en)	2021-12-17	2023-06-22	Shanghai Henlius Biotech, Inc.	Anti-ox40 antibodies, multispecific antibodies and methods of use
CR20240246A (es)	2021-12-20	2024-07-19	Hoffmann La Roche	Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden
IL314129A (en)	2022-01-07	2024-09-01	Johnson & Johnson Entpr Innovation Inc	Materials and methods of IL-1BETA binding proteins
TW202340251A (zh)	2022-01-19	2023-10-16	美商建南德克公司	抗ｎｏｔｃｈ２抗體及結合物及其使用方法
WO2023154824A1 (en)	2022-02-10	2023-08-17	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Human monoclonal antibodies that broadly target coronaviruses
AR128540A1 (es)	2022-02-16	2024-05-22	Ac Immune Sa	Moléculas de unión anti-tdp-43 humanizadas y usos de las mismas
TW202342510A (zh)	2022-02-18	2023-11-01	英商Ｒｑ生物科技有限公司	抗體
MX2024010003A (es)	2022-02-18	2024-09-30	Rakuten Medical Inc	Moléculas de anticuerpo anti-ligando 1 de muerte programada (pd-l1), polinucleótidos que las codifican y métodos de uso.
WO2023161877A1 (en)	2022-02-25	2023-08-31	Glaxosmithkline Intellectual Property Development Limited	Cytotoxicity targeting chimeras for integrin avb6-expressing cells
WO2023161879A1 (en)	2022-02-25	2023-08-31	Glaxosmithkline Intellectual Property Development Limited	Cytotoxicity targeting chimeras for fibroblast activation protein-expressing cells
WO2023161876A1 (en)	2022-02-25	2023-08-31	Glaxosmithkline Intellectual Property Development Limited	Cytotoxicity targeting chimeras for cxcr3-expressing cells
WO2023161881A1 (en)	2022-02-25	2023-08-31	Glaxosmithkline Intellectual Property Development Limited	Cytotoxicity targeting chimeras for ccr2-expressing cells
WO2023161875A1 (en)	2022-02-25	2023-08-31	Glaxosmithkline Intellectual Property Development Limited	Cytotoxicity targeting chimeras for prostate specific membrane antigen-expressing cells
KR20240149439A (ko)	2022-02-25	2024-10-14	글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드	C-c 케모카인 수용체 2-발현 세포에 대한 세포독성 표적화 키메라
WO2023161878A1 (en)	2022-02-25	2023-08-31	Glaxosmithkline Intellectual Property Development Limited	Cytotoxicity targeting chimeras for folate receptor-expressing cells
WO2023173026A1 (en)	2022-03-10	2023-09-14	Sorrento Therapeutics, Inc.	Antibody-drug conjugates and uses thereof
IL314211A (en)	2022-03-23	2024-09-01	Genentech Inc	Combined treatment of bispecific antibody and chemotherapy against CD20/ANTI-CD3
AU2023240941A1 (en)	2022-03-25	2024-09-19	Shanghai Henlius Biologics Co., Ltd.	Anti-msln antibodies and methods of use
WO2023192827A1 (en)	2022-03-26	2023-10-05	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Bispecific antibodies to hiv-1 env and their use
WO2023186756A1 (en)	2022-03-28	2023-10-05	F. Hoffmann-La Roche Ag	Interferon gamma variants and antigen binding molecules comprising these
WO2023192881A1 (en)	2022-03-28	2023-10-05	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Neutralizing antibodies to hiv-1 env and their use
IL316022A (en)	2022-03-30	2024-11-01	Janssen Biotech Inc	A method for the treatment of mild to moderate psoriasis with a specific IL-23 antibody
GB202204813D0 (en)	2022-04-01	2022-05-18	Bradcode Ltd	Human monoclonal antibodies and methods of use thereof
IL315770A (en)	2022-04-01	2024-11-01	Genentech Inc	Dosage for treatment with bispecific anti-FCRH5/anti-CD3 antibodies
WO2023194565A1 (en)	2022-04-08	2023-10-12	Ac Immune Sa	Anti-tdp-43 binding molecules
AU2023253705A1 (en)	2022-04-13	2024-10-17	F. Hoffmann-La Roche Ag	Pharmaceutical compositions of therapeutic proteins and methods of use
WO2023198727A1 (en)	2022-04-13	2023-10-19	F. Hoffmann-La Roche Ag	Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use
AU2023258146A1 (en)	2022-04-20	2024-09-05	Kantonsspital St. Gallen	Antibodies or antigen-binding fragments pan-specifically binding to gremlin-1 and gremlin-2 and uses thereof
WO2023209177A1 (en)	2022-04-29	2023-11-02	Astrazeneca Uk Limited	Sars-cov-2 antibodies and methods of using the same
AR129182A1 (es)	2022-04-29	2024-07-24	23Andme Inc	Proteínas de unión al antígeno
TW202406934A (zh)	2022-05-03	2024-02-16	美商建南德克公司	抗Ｌｙ６Ｅ抗體、免疫結合物及其用途
WO2023219613A1 (en)	2022-05-11	2023-11-16	Genentech, Inc.	Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
AR129268A1 (es)	2022-05-11	2024-08-07	Hoffmann La Roche	Anticuerpo que se une a vegf-a e il6 y métodos de uso
US20230374122A1 (en)	2022-05-18	2023-11-23	Janssen Biotech, Inc.	Method for Evaluating and Treating Psoriatic Arthritis with IL23 Antibody
AR129445A1 (es)	2022-05-27	2024-08-28	Glaxosmithkline Ip Dev Ltd	USO DE PROTEÍNAS DE UNIÓN A TNF-a Y PROTEÍNAS DE UNIÓN A IL-7 EN EL TRATAMIENTO MÉDICO
WO2023235699A1 (en)	2022-05-31	2023-12-07	Jounce Therapeutics, Inc.	Antibodies to lilrb4 and uses thereof
WO2023240058A2 (en)	2022-06-07	2023-12-14	Genentech, Inc.	Prognostic and therapeutic methods for cancer
WO2023237706A2 (en)	2022-06-08	2023-12-14	Institute For Research In Biomedicine (Irb)	Cross-specific antibodies, uses and methods for discovery thereof
WO2024015897A1 (en)	2022-07-13	2024-01-18	Genentech, Inc.	Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
TW202413433A (zh)	2022-07-19	2024-04-01	美商建南德克公司	用抗ｆｃｒｈ５／抗ｃｄ３雙特異性抗體進行治療之給藥
WO2024020407A1 (en)	2022-07-19	2024-01-25	Staidson Biopharma Inc.	Antibodies specifically recognizing b- and t-lymphocyte attenuator (btla) and uses thereof
WO2024020564A1 (en)	2022-07-22	2024-01-25	Genentech, Inc.	Anti-steap1 antigen-binding molecules and uses thereof
TW202423992A (zh)	2022-07-22	2024-06-16	美商必治妥美雅史谷比公司	結合至人類pad4之抗體及其用途
WO2024030829A1 (en)	2022-08-01	2024-02-08	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Monoclonal antibodies that bind to the underside of influenza viral neuraminidase
WO2024028731A1 (en)	2022-08-05	2024-02-08	Janssen Biotech, Inc.	Transferrin receptor binding proteins for treating brain tumors
WO2024028732A1 (en)	2022-08-05	2024-02-08	Janssen Biotech, Inc.	Cd98 binding constructs for treating brain tumors
WO2024042112A1 (en)	2022-08-25	2024-02-29	Glaxosmithkline Intellectual Property Development Limited	Antigen binding proteins and uses thereof
WO2024044779A2 (en)	2022-08-26	2024-02-29	Juno Therapeutics, Inc.	Antibodies and chimeric antigen receptors specific for delta-like ligand 3 (dll3)
WO2024049949A1 (en)	2022-09-01	2024-03-07	Genentech, Inc.	Therapeutic and diagnostic methods for bladder cancer
WO2024054822A1 (en)	2022-09-07	2024-03-14	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Engineered sars-cov-2 antibodies with increased neutralization breadth
WO2024054929A1 (en)	2022-09-07	2024-03-14	Dynamicure Biotechnology Llc	Anti-vista constructs and uses thereof
WO2024064826A1 (en)	2022-09-22	2024-03-28	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
WO2024068996A1 (en)	2022-09-30	2024-04-04	Centre Hospitalier Universitaire Vaudois (C.H.U.V.)	Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
WO2024077239A1 (en)	2022-10-07	2024-04-11	Genentech, Inc.	Methods of treating cancer with anti-c-c motif chemokine receptor 8 (ccr8) antibodies
TW202426505A (zh)	2022-10-25	2024-07-01	美商建南德克公司	癌症之治療及診斷方法
WO2024097741A1 (en)	2022-11-04	2024-05-10	Gilead Sciences, Inc.	Anticancer therapies using anti-ccr8 antibody, chemo and immunotherapy combinations
WO2024102734A1 (en)	2022-11-08	2024-05-16	Genentech, Inc.	Compositions and methods of treating childhood onset idiopathic nephrotic syndrome
WO2024100200A1 (en)	2022-11-09	2024-05-16	Cis Pharma Ag	Anti-l1-cam antibodies and their uses for diagnostic and therapeutic applications
WO2024100170A1 (en)	2022-11-11	2024-05-16	F. Hoffmann-La Roche Ag	Antibodies binding to hla-a*02/foxp3
US20240226313A1 (en)	2022-11-17	2024-07-11	Sanofi	Ceacam5 antibody-drug conjugates and methods of use thereof
WO2024110898A1 (en)	2022-11-22	2024-05-30	Janssen Biotech, Inc.	Method of treating ulcerative colitis with anti-il23 specific antibody
WO2024137381A1 (en)	2022-12-19	2024-06-27	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Monoclonal antibodies for treating sars-cov-2 infection
WO2024133940A2 (en)	2022-12-23	2024-06-27	Iomx Therapeutics Ag	Cross-specific antigen binding proteins (abp) targeting leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2, combinations and uses thereof
US20240360229A1 (en)	2023-01-18	2024-10-31	Genentech, Inc.	Multispecific antibodies and uses thereof
WO2024156672A1 (en)	2023-01-25	2024-08-02	F. Hoffmann-La Roche Ag	Antibodies binding to csf1r and cd3
WO2024167898A1 (en)	2023-02-07	2024-08-15	Go Therapeutics, Inc.	ANTIBODY FUSION PROTEINS COMPRISING ANTI-GLYCO-MUC4 ANTIBODIES AND MIC PROTEIN α1-α2 DOMAINS, AND THEIR USES
WO2024184494A1 (en)	2023-03-08	2024-09-12	Ac Immune Sa	Anti-tdp-43 binding molecules and uses thereof
EP4428159A1 (en)	2023-03-10	2024-09-11	Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l.	Melanoma targeting human antibodies and therapeutic uses thereof
EP4428158A1 (en)	2023-03-10	2024-09-11	Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l.	Lung cancer targeting human antibodies and therapeutic uses thereof
WO2024191785A1 (en)	2023-03-10	2024-09-19	Genentech, Inc.	Fusions with proteases and uses thereof
WO2024188965A1 (en)	2023-03-13	2024-09-19	F. Hoffmann-La Roche Ag	Combination therapy employing a pd1-lag3 bispecific antibody and an hla-g t cell bispecific antibody
US20240327522A1 (en)	2023-03-31	2024-10-03	Genentech, Inc.	Anti-alpha v beta 8 integrin antibodies and methods of use
WO2024211234A1 (en)	2023-04-05	2024-10-10	Sorrento Therapeutics, Inc.	Antibody-drug conjugates and uses thereof
WO2024211235A1 (en)	2023-04-05	2024-10-10	Sorrento Therapeutics, Inc.	Antibody-drug conjugates and uses thereof
WO2024211236A2 (en)	2023-04-05	2024-10-10	Sorrento Therapeutics, Inc.	Antibody-drug conjugates and uses thereof
WO2024212827A1 (en)	2023-04-12	2024-10-17	Shanghai Kangabio Co., Limited	Multifunctional molecules comprising masked interleukin 12 and methods of use
WO2024220546A2 (en)	2023-04-17	2024-10-24	Peak Bio, Inc.	Antibodies and antibody-drug conjugates and methods of use and synthetic processes and intermediates
WO2024218345A1 (en)	2023-04-21	2024-10-24	Glaxosmithkline Intellectual Property Development Limited	Cytotoxicity targeting chimeras for antibody-drug conjugates and bispecific antibodies
WO2024218361A1 (en)	2023-04-21	2024-10-24	Glaxosmithkline Intellectual Property Development Limited	Bispecific cytotoxicity targeting chimeras

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4215051A (en) *	1979-08-29	1980-07-29	Standard Oil Company (Indiana)	Formation, purification and recovery of phthalic anhydride
KR850004274A (ko) *	1983-12-13	1985-07-11	원본미기재	에리트로포이에틴의 제조방법
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US4978745A (en) *	1987-11-23	1990-12-18	Centocor, Inc.	Immunoreactive heterochain antibodies
US5047335A (en) *	1988-12-21	1991-09-10	The Regents Of The University Of Calif.	Process for controlling intracellular glycosylation of proteins
CA2057010C (en) *	1989-05-25	2002-08-06	Paul B. Chapman	Anti-idiotypic antibody which induces an immune response against a glycosphingolipid and use thereof
DE4028800A1 (de)	1990-09-11	1992-03-12	Behringwerke Ag	Gentechnische sialylierung von glykoproteinen
US5558865A (en)	1991-08-22	1996-09-24	Nissin Shokuhin Kabushiki Kaisha	HIV immunotherapeutics
US5753229A (en) *	1991-09-25	1998-05-19	Mordoh; Jose	Monoclonal antibodies reactive with tumor proliferating cells
US5958403A (en) *	1992-02-28	1999-09-28	Beth Israel Hospital Association	Methods and compounds for prevention of graft rejection
US5736137A (en) *	1992-11-13	1998-04-07	Idec Pharmaceuticals Corporation	Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
PT752248E (pt)	1992-11-13	2001-01-31	Idec Pharma Corp	Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b
DE69419721T2 (de)	1993-01-12	2000-04-27	Biogen, Inc.	Rekombinante anti-vla4 antikörpermoleküle
WO1995024494A1 (en)	1994-03-09	1995-09-14	Abbott Laboratories	Humanized milk
US5811524A (en) *	1995-06-07	1998-09-22	Idec Pharmaceuticals Corporation	Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
JP3606536B2 (ja) *	1995-11-17	2005-01-05	タカラバイオ株式会社	ウイルス複製抑制剤
GB9603256D0 (en) *	1996-02-16	1996-04-17	Wellcome Found	Antibodies
CA2264953C (en)	1996-08-16	2008-09-30	The Texas A & M University System	Modifying insect cell gylcosylation pathways with baculovirus expression vectors
US6306393B1 (en)	1997-03-24	2001-10-23	Immunomedics, Inc.	Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6183744B1 (en) *	1997-03-24	2001-02-06	Immunomedics, Inc.	Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US5952203A (en) *	1997-04-11	1999-09-14	The University Of British Columbia	Oligosaccharide synthesis using activated glycoside derivative, glycosyl transferase and catalytic amount of nucleotide phosphate
ES2340112T3 (es) *	1998-04-20	2010-05-28	Glycart Biotechnology Ag	Ingenieria de glicosilacion de anticuerpos para la mejora de la citotoxicidad celular dependiente de anticuerpos.
US6946292B2 (en)	2000-10-06	2005-09-20	Kyowa Hakko Kogyo Co., Ltd.	Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CA2442801A1 (en) *	2001-04-02	2002-10-10	Idec Pharmaceutical Corporation	Recombinant antibodies coexpressed with gntiii
PL217751B1 (pl) *	2001-08-03	2014-08-29	Glycart Biotechnology Ag	Zastosowanie glikomodyfikowanego przeciwciała do wytwarzania kompozycji farmaceutycznej do leczenia choroby wybranej z grupy składającej się z nowotworu, małopłytkowości autoimmunologicznej w przewlekłej chorobie przeszczep przeciwko gospodarzowi i immunozależnej nabytej aplazji czysto czerwonokrwinkowej
SG179292A1 (en)	2003-01-22	2012-04-27	Roche Glycart Ag	Fusion constructs and use of same to produce antibodies with increased fc receptor binding affinity and effector function
NZ588860A (en)	2003-11-05	2012-03-30	Roche Glycart Ag	CD20 antibodies with increased Fc receptor binding affinity and effector function
TWI387602B (zh)	2005-02-07	2013-03-01	Roche Glycart Ag	與上皮生長因子受體（ｅｇｆｒ）結合之抗原結合分子，編碼該抗原結合分子之載體及其用途
RU2482132C2 (ru)	2005-08-26	2013-05-20	Роше Гликарт Аг	Модифицированные антигенсвязывающие молекулы с измененной клеточной сигнальной активностью
AR062223A1 (es)	2006-08-09	2008-10-22	Glycart Biotechnology Ag	Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
AU2010288469A1 (en)	2009-08-31	2012-03-01	Roche Glycart Ag	Affinity-matured humanized anti CEA monoclonal antibodies

2002
- 2002-08-05 PL PL374178A patent/PL217751B1/pl unknown
- 2002-08-05 WO PCT/US2002/024739 patent/WO2003011878A2/en active Application Filing
- 2002-08-05 IL IL16017002A patent/IL160170A0/xx unknown
- 2002-08-05 NZ NZ531219A patent/NZ531219A/en not_active IP Right Cessation
- 2002-08-05 JP JP2003517069A patent/JP2005524379A/ja active Pending
- 2002-08-05 CN CNA028181735A patent/CN1555411A/zh active Pending
- 2002-08-05 CA CA2838062A patent/CA2838062C/en not_active Expired - Lifetime
- 2002-08-05 EP EP20100000043 patent/EP2180044A1/en not_active Ceased
- 2002-08-05 NZ NZ592087A patent/NZ592087A/xx not_active IP Right Cessation
- 2002-08-05 CA CA2455365A patent/CA2455365C/en not_active Expired - Lifetime
- 2002-08-05 NZ NZ571596A patent/NZ571596A/en not_active IP Right Cessation
- 2002-08-05 US US10/211,554 patent/US20030175884A1/en not_active Abandoned
- 2002-08-05 RU RU2004106559/13A patent/RU2321630C2/ru active
- 2002-08-05 AU AU2002339845A patent/AU2002339845B2/en not_active Expired
- 2002-08-05 HU HU0700103A patent/HUP0700103A3/hu not_active Application Discontinuation
- 2002-08-05 EP EP02778191A patent/EP1423510A4/en not_active Withdrawn
- 2002-08-05 NZ NZ581474A patent/NZ581474A/en not_active IP Right Cessation
- 2002-08-05 MX MXPA04001072A patent/MXPA04001072A/es active IP Right Grant
- 2002-08-05 KR KR10-2004-7001617A patent/KR20040054669A/ko not_active Application Discontinuation
- 2002-08-05 KR KR1020107000746A patent/KR20100018071A/ko active Search and Examination
- 2002-08-05 NZ NZ603111A patent/NZ603111A/en not_active IP Right Cessation
2004
- 2004-02-02 NO NO20040453A patent/NO332457B1/no not_active IP Right Cessation
- 2004-02-02 IL IL160170A patent/IL160170A/en unknown
2005
- 2005-08-09 US US11/199,232 patent/US8021856B2/en not_active Expired - Fee Related
2008
- 2008-12-25 JP JP2008331038A patent/JP2009114201A/ja active Pending
2011
- 2011-08-02 US US13/196,724 patent/US8999324B2/en not_active Expired - Fee Related
2015
- 2015-03-23 US US14/665,191 patent/US9321843B2/en not_active Expired - Fee Related
2016
- 2016-03-24 US US15/080,020 patent/US9631023B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
MXPA04001072A (es)	2005-02-17
IL160170A0 (en)	2004-07-25
HUP0700103A2 (en)	2007-05-02
NZ603111A (en)	2014-05-30
PL217751B1 (pl)	2014-08-29
EP2180044A1 (en)	2010-04-28
JP2005524379A (ja)	2005-08-18
US20030175884A1 (en)	2003-09-18
CA2838062C (en)	2015-12-22
EP1423510A4 (en)	2005-06-01
KR20040054669A (ko)	2004-06-25
NO332457B1 (no)	2012-09-24
HUP0700103A3 (en)	2012-09-28
IL160170A (en)	2009-05-04
KR20100018071A (ko)	2010-02-16
US8021856B2 (en)	2011-09-20
AU2002339845B2 (en)	2009-03-26
PL374178A1 (en)	2005-10-03
CN1555411A (zh)	2004-12-15
NZ581474A (en)	2011-04-29
NZ531219A (en)	2007-07-27
US20080280322A9 (en)	2008-11-13
WO2003011878A3 (en)	2003-11-06
US20050272128A1 (en)	2005-12-08
CA2838062A1 (en)	2003-02-13
US9631023B2 (en)	2017-04-25
US20150274837A1 (en)	2015-10-01
WO2003011878A2 (en)	2003-02-13
RU2004106559A (ru)	2005-05-10
JP2009114201A (ja)	2009-05-28
NZ592087A (en)	2012-11-30
NZ571596A (en)	2010-11-26
US9321843B2 (en)	2016-04-26
EP1423510A2 (en)	2004-06-02
RU2321630C2 (ru)	2008-04-10
US20110293609A1 (en)	2011-12-01
CA2455365A1 (en)	2003-02-13
US20160272719A1 (en)	2016-09-22
US8999324B2 (en)	2015-04-07
CA2455365C (en)	2014-07-29

Publication	Publication Date	Title
NO20040453L (no)	2004-03-30	Antistoff glykosyleringsvarianter med okt antistoff-avhengig cellulaer cytotoksisitet
DE60220542D1 (de)	2007-07-19	Fördereinrichtung
IS6982A (is)	2003-10-08	Mótefni gegn VLA-1
DE60237865D1 (de)	2010-11-18	Wippschalter
DK1421841T3 (da)	2007-12-17	Mejetærsker
DE60205829T2 (de)	2006-06-14	Kette
DE60202930D1 (de)	2005-03-17	Schwinghebel
EE200300569A (et)	2004-04-15	CD44v6-spetsiifilised antikehad
DE60207950T2 (de)	2006-06-14	Reflektor
DE60235930D1 (de)	2010-05-27	Reflektorantenne
DE60204946D1 (de)	2005-08-11	Reflektorantenne
DE50200198D1 (de)	2004-02-12	Synchronisiereinrichtung
DE60214100D1 (de)	2006-10-05	Verzögerungsregelschleife
DE50200695D1 (de)	2004-09-02	Beriemungssystem
DE60230658D1 (de)	2009-02-12	Stigkeit
DE10195943T1 (de)	2003-08-07	Fördergerät
DE50201460D1 (de)	2004-12-09	Fördereinrichtung
DE60126833D1 (de)	2007-04-05	Flugzeugsitzkonstruktion
ATA2892002A (de)	2005-08-15	Beschlag
DE50211015D1 (de)	2007-11-15	Antitumor wirksame 2-alkoxyestradiolsulfamate
DE60205000D1 (de)	2005-08-18	Fördervorrichtung
DE50104046D1 (de)	2004-11-11	Sägeband
DK200100172U3 (da)	2001-08-24	Pavillon
UA5324S (uk)	2001-11-15	Браслет
SE0102911D0 (sv)	2001-09-03	Tråg

Legal Events

Date	Code	Title	Description
2022-08-15	MK1K	Patent expired